<?xml version="1.0" encoding="UTF-8"?>
<Bundle xmlns="http://hl7.org/fhir" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://hl7.org/fhir https://hl7.org/fhir/fhir-single.xsd">
	<id value="44930798-7856-4dbf-968d-58feb74c3b99" />
	<identifier> 
		<system value="urn:example-org:glemser.identifiers"/> 
		<value value="35f23e97-328c-4eb7-8e94-34f478983e89"/> 
	</identifier>
	<type value="message" />
	<entry>
		<fullUrl value="MessageHeader/31fb0e0a-ca8b-4554-bd4c-0f61004a89fb" />
		<resource>
			<MessageHeader>
				<id value="31fb0e0a-ca8b-4554-bd4c-0f61004a89fb" />
				<eventCoding>
					<display value="temp-string of VIB Demo Labeling" />
				</eventCoding>
				<destination>
					<receiver>
						<reference value="Organization/FDAID" />
					</receiver>
				</destination>
				<sender>
					<reference value="Organization/PfizerId" />
				</sender>
				<source>
					<name value="VIB Demo" />
				</source> 
			</MessageHeader>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Task/bd675726-6ca7-4fce-8edb-6f29c0df2bcc" />
		<resource>
			<Task>
				<id value="bd675726-6ca7-4fce-8edb-6f29c0df2bcc" />
				<identifier>
					<system value="http://example.com/system" />
					<value value="bd675726-6ca7-4fce-8edb-6f29c0df2bcc" />
				</identifier>
				<groupIdentifier>
					<system value="http://example.com/system" />
					<value value="NDA 212436" />
				</groupIdentifier>
				<status value="requested" />
				<intent value="order" />
				<code>
					<coding>
						<system value="https://www.accessdata.fda.gov/eCTD-temp" />
						<code value="fdaat1" />
						<display value="New Drug Application (NDA)" />
					</coding>
					<coding>
						<system value="https://www.accessdata.fda.gov/eCTD-temp" />
						<code value="fdast1" />
						<display value="Original Application" />
					</coding>
					<!-- new code does not exist yet, new workflow to be adopted. -->
					<coding>
						<system value="https://www.accessdata.fda.gov/eCTD-temp" />
						<code value="fdaat1FAKEcode" />
						<display value="New Drug Application (NDA) - process start" />
					</coding>
					<text value="NDA Labeling Initial Submission from Pharmaceutical agent" />
				</code>
				<description value="Initial Submission: supplemental new drug application (sNDA) to add information to section XX and remove information from section YY" />
				<for>
					<reference value="Organization/PfizerId" />
				</for>
				<requester>
					<reference value="Organization/PfizerId" />
				</requester>
				<requestedPerformer>
					<reference>
						<reference value="Organization/FDAID" />
					</reference>
				</requestedPerformer>
				<owner>
					<reference value="Organization/FDAID" />
				</owner>
				<input>
					<type>
						<coding>
							<system value="http://loinc.org" />
							<code value="34391-3" />
							<display value="FDA product label Human prescription drug label" />
						</coding>
						<text value="FDA product label Human prescription drug label" />
					</type>
					<!-- reference to document bundle in this document that contains the label being submitted -->
					<valueReference>
						<reference value="Bundle/bundle-ibrance75-100-125-g" />
					</valueReference>
				</input>
			</Task>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Bundle/bundle-ibrance75-100-125-g" />
		<resource>
			<Bundle>
				<id value="bundle-ibrance75-100-125-g" />
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi" />
				</meta>
				<identifier>
					<system value="https://www.fda.gov/" />
					<value value="ibrance-g" />
				</identifier>
				<type value="document" />
				<timestamp value="2022-09-08T00:00:00Z" />
			<entry>
		<fullUrl value="Composition/compositionusen"/>
		<resource>
			<Composition>
				<id value="compositionusen"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
				</meta>
				<language value="en"/>
				<text>
					<status value="generated"/>
					<div xmlns="http://www.w3.org/1999/xhtml">These highlights do not include all the information needed
                        to use IBRANCE safely and effectively. See full prescribing information for IBRANCE. <br/>
                        <br/>IBRANCE<sup>®</sup> (palbociclib) capsules, for oral use <br/>Initial U.S. Approval: 2015
                    </div>
				</text>
				<version value="15"/>
				<contained>
					<Binary>
						<id value="ibrance-01"/>
						<contentType value="image/jpg"/>
						<data value="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"/>
					</Binary>
				</contained>
				<extension url="http://hl7.org/fhir">
					<valueReference>
						<reference value="#ibrance-01"/>
					</valueReference>
				</extension>
				
				<identifier>
					<system value="https://www.fda.gov/"/>
					<value value="2de9790e-3eb6-49ca-a35b-7b42c569f794"/>
				</identifier>
				<status value="final"/>
				<type>
					<coding>
						<system value="http://loinc.org"/>
						<code value="34391-3"/>
						<display value="HUMAN PRESCRIPTION DRUG LABEL"/>
					</coding>
				</type>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<date value="2022-09-08T00:00:00Z"/>
				<author>
					<reference value="Organization/134489525"/>
				</author>
				<title value="Drug Label for IBRANCE (palbociclib) film coated tablets"/>
				<section id="4a7f4ea7-edd4-42b9-8f79-20cbdcfac3a5">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="ID_9e4d1989-7184-46ce-a222-1b221d893f7d"/>
					</extension>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="43683-2"/>
							<display value="RECENT MAJOR CHANGES SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<table width="100%">
									<colgroup span="2">
										<col width="85%"/>
										<col width="15%"/>
									</colgroup>
									<tbody>
										<tr>
											<td style="text-align: left; text-align: left; ">
												<p>Indications and Usage (<a href="#ID_RefS1">1</a>)</p>
											</td>
											<td style="text-align: center; text-align: center; " align="center">
												<p style="text-align: center; ">12/2022</p>
											</td>
										</tr>
										<tr>
											<td style="text-align: left; text-align: left; ">
												<p>Dosage and Administration (<a href="#ID_RefS2.1">2.1</a>)</p>
											</td>
											<td style="text-align: center; text-align: center; " align="center">
												<p style="text-align: center; ">12/2022</p>
											</td>
										</tr>
									</tbody>
								</table>
							</div>
						</div>
					</text>
				</section>
				<section id="50d48d6d-036f-4b2a-843e-390340f8c6b9">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S1"/>
					</extension>
					<title value="1 INDICATIONS AND USAGE"/>
					<code>
                        <coding>
							<system value="http://loinc.org"/>
							<code value="34067-9"/>
							<display value="INDICATIONS &amp; USAGE SECTION"/>
						</coding>
                    </code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<p>IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with
                                    hormone receptor (HR)-positive, human epidermal growth factor receptor 2
                                    (HER2)-negative advanced or metastatic breast cancer in combination with:</p>
								<ul>
									<li>an aromatase inhibitor as initial endocrine-based therapy (<a href="#ID_RefS1">1</a>); or</li>
									<li>fulvestrant in patients with disease progression following endocrine therapy.
                                        (<a href="#ID_RefS1">1</a>)</li>
								</ul>
							</div>
							<div style="narrative">
								<p>IBRANCE is indicated for the treatment of adult patients with hormone receptor
                                    (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or
                                    metastatic breast cancer in combination with:</p>
								<ul>
									<li id="_RefS1">an aromatase inhibitor as initial endocrine-based therapy; or</li>
									<li>fulvestrant in patients with disease progression following endocrine therapy.
                                    </li>
								</ul>
							</div>
						</div>
					</text>
				</section>
				<section id="0798fd83-eca9-4dc5-960f-475b14fefab2">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2023-09-13"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S2"/>
					</extension>
					<title value="2 DOSAGE AND ADMINISTRATION"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34068-7"/>
							<display value="DOSAGE &amp; ADMINISTRATION SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<p>IBRANCE capsules are taken orally with food in combination with an aromatase
                                    inhibitor or fulvestrant. (<a href="#S2.2">2</a>)</p>
								<ul>
									<li>Recommended starting dose: 125 mg once daily taken with food for 21 days
                                        followed by 7 days off treatment. (<a href="#ID_RefS2.1">2.1</a>)</li>
									<li>Dosing interruption and/or dose reductions are recommended based on individual
                                        safety and tolerability. (<a href="#ID_RefS2.2">2.2</a>)</li>
								</ul>
							</div>
						</div>
					</text>
					<section id="3df707b5-7811-412e-81c7-ac3cf3ed0d68">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S2.1"/>
						</extension>
						<title value="2.1Recommended Dose and Schedule"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for
                                        21 consecutive days followed by 7 days off treatment to comprise a complete
                                        cycle of 28 days. IBRANCE should be taken with food <em>[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</em>.</p>
									<p>Administer the recommended dose of an aromatase inhibitor when given with
                                        IBRANCE. Please refer to the Full Prescribing Information for the aromatase
                                        inhibitor being used.</p>
									<p>When given with IBRANCE, the recommended dose of fulvestrant is 500 mg
                                        administered on Days 1, 15, 29, and once monthly thereafter. Please refer to the
                                        Full Prescribing Information of fulvestrant.</p>
									<p>Patients should be encouraged to take their dose of IBRANCE at approximately the
                                        same time each day.</p>
									<p>If the patient vomits or misses a dose, an additional dose should not be taken.
                                        The next prescribed dose should be taken at the usual time. IBRANCE capsules
                                        should be swallowed whole (do not chew, crush, or open them prior to
                                        swallowing). Capsules should not be ingested if they are broken, cracked, or
                                        otherwise not intact.</p>
									<p>Pre/perimenopausal women treated with the combination IBRANCE plus <span>an
                                            aromatase inhibitor or </span>fulvestrant therapy should also be treated
                                        with luteinizing hormone-releasing hormone (LHRH) agonists according to current
                                        clinical practice standards.</p>
									<p>For men treated with combination IBRANCE plus aromatase inhibitor therapy,
                                        consider treatment with an LHRH agonist according to current clinical practice
                                        standards.</p>
								</div>
							</div>
						</text>
					</section>
					<section id="02299b20-59f0-4e22-b0b7-1a4ced375ef9">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S2.2"/>
						</extension>
						<title value="2.2Dose Modification"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>The recommended dose modifications for adverse reactions are listed in Tables 1,
                                        2, and 3.</p>
									<table width="70%">
										<caption>Table 1. Recommended Dose Modification for Adverse Reactions</caption>
										<colgroup span="2">
											<col width="38%"/>
											<col width="43%"/>
										</colgroup>
										<thead>
											<tr>
												<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
													<strong>Dose Level</strong>
												</td>
												<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
													<strong>Dose</strong>
												</td>
											</tr>
										</thead>
										<tbody>
											<tr>
												<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
													<p>Recommended starting dose</p>
												</td>
												<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
													<p style="text-align: center; ">125 mg/day</p>
												</td>
											</tr>
											<tr>
												<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
													<p>First dose reduction</p>
												</td>
												<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
													<p style="text-align: center; ">100 mg/day</p>
												</td>
											</tr>
											<tr>
												<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
													<p>Second dose reduction</p>
												</td>
												<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
													<p style="text-align: center; ">75 mg/day<a href="#_RefID0EWWAE" id="ID0EY4BG" name="foot-ref-_RefID0EWWAE">
															<sup>1</sup>
														</a>
                                                    </p>
												</td>
											</tr>
										</tbody>
									</table>
									<p><sup>
											<a name="_RefID0EWWAE" href="#foot-ref-_RefID0EWWAE">1</a>
										</sup>If further
                                        dose reduction below 75 mg/day is required, discontinue.</p>
									<table width="80%">
										<caption>Table 2. Dose Modification and Management – Hematologic Toxicities<a href="#_RefID0E2WAE" id="ID0EDOAI" name="foot-ref-_RefID0E2WAE">
												<sup>1</sup>
											</a></caption>
										<colgroup span="2">
											<col width="19%"/>
											<col width="73%"/>
										</colgroup>
										<tfoot>
											<tr>
												<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="2">Grading according to CTCAE 4.0.<br/>CTCAE=Common
                                                    Terminology Criteria for Adverse Events; LLN=lower limit of normal.
                                                </td>
											</tr>
										</tfoot>
										<tbody>
											<tr>
												<td colspan="2" style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: left; ">
													<p>Monitor complete blood counts prior to the start of IBRANCE
                                                        therapy and at the beginning of each cycle, as well as on Day 15
                                                        of the first 2 cycles, and as clinically indicated.<br/>For
                                                        patients who experience a maximum of Grade 1 or 2 neutropenia in
                                                        the first 6 cycles, monitor complete blood counts for subsequent
                                                        cycles every 3 months, prior to the beginning of a cycle and as
                                                        clinically indicated.</p>
												</td>
											</tr>
											<tr>
												<td style="text-align: center; border-right: solid; border-left: solid; border-bottom: solid; text-align: center; " align="center">
													<p style="text-align: center; ">
														<strong>CTCAE Grade</strong>
													</p>
												</td>
												<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
													<p style="text-align: center; ">
														<strong>Dose Modifications</strong>
													</p>
												</td>
											</tr>
											<tr>
												<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
													<p>Grade 1 or 2</p>
												</td>
												<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
													<p>No dose adjustment is required.</p>
												</td>
											</tr>
											<tr>
												<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
													<p>Grade 3</p>
												</td>
												<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
													<p><span style="text-decoration: underline; ">Day 1 of
                                                            cycle</span>:<br/>Withhold IBRANCE, repeat complete blood
                                                        count monitoring within 1 week. When recovered to Grade ≤2,
                                                        start the next cycle at the <em>same dose</em>.<br/><span style="text-decoration: underline; ">Day 15 of first 2
                                                            cycles</span>:<br/>If Grade 3 on Day 15, continue IBRANCE
                                                        at current dose to complete cycle and repeat complete blood
                                                        count on Day 22.<br/>If Grade 4 on Day 22, see dose
                                                        modification guidelines below.<br/>Consider dose reduction in
                                                        cases of prolonged (&gt;1 week) recovery from Grade 3
                                                        neutropenia or recurrent Grade 3 neutropenia on Day 1 of
                                                        subsequent cycles.</p>
												</td>
											</tr>
											<tr>
												<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
													<p>Grade 3 neutropenia<a href="#_RefID0EHZAE" id="ID0E3OAI" name="foot-ref-_RefID0EHZAE">
															<sup>1</sup>
														</a> with fever
                                                        ≥38.5 ºC and/or infection</p>
												</td>
												<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
													<p><span style="text-decoration: underline; ">At any
                                                            time</span>:<br/>Withhold IBRANCE until recovery to Grade
                                                        ≤2.<br/>Resume at the <em>next lower dose</em>.</p>
												</td>
											</tr>
											<tr>
												<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
													<p>Grade 4</p>
												</td>
												<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
													<p><span style="text-decoration: underline; ">At any
                                                            time</span>:<br/>Withhold IBRANCE until recovery to Grade
                                                        ≤2.<br/>Resume at the <em>next lower dose</em>.</p>
												</td>
											</tr>
										</tbody>
									</table>
									<p><sup>
											<a name="_RefID0E2WAE" href="#foot-ref-_RefID0E2WAE">1</a>
										</sup>Table
                                        applies to all hematologic adverse reactions except lymphopenia (unless
                                        associated with clinical events, e.g., opportunistic infections).</p>
									<p><sup>
											<a name="_RefID0EHZAE" href="#foot-ref-_RefID0EHZAE">2</a>
										</sup>Absolute
                                        neutrophil count (ANC): Grade 1: ANC &lt; LLN - 1500/mm<sup>3</sup>; Grade 2:
                                        ANC 1000 - &lt;1500/mm<sup>3</sup>; Grade 3: ANC 500 - &lt;1000/mm<sup>3</sup>;
                                        Grade 4: ANC &lt;500/mm<sup>3</sup>.</p>
									<table width="70%">
										<caption>Table 3. Dose Modification and Management – Non-Hematologic Toxicities
                                        </caption>
										<colgroup span="2">
											<col width="36%"/>
											<col width="45%"/>
										</colgroup>
										<thead>
											<tr>
												<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
													<strong>CTCAE Grade</strong>
												</td>
												<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
													<strong>Dose Modifications</strong>
												</td>
											</tr>
										</thead>
										<tfoot>
											<tr>
												<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="2">Grading according to CTCAE 4.0.<br/>CTCAE=Common
                                                    Terminology Criteria for Adverse Events.</td>
											</tr>
										</tfoot>
										<tbody>
											<tr>
												<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
													<p>Grade 1 or 2</p>
												</td>
												<td style="text-align: left; border-right: solid; border-top: solid; border-bottom: solid; text-align: left; ">
													<p>No dose adjustment is required.</p>
												</td>
											</tr>
											<tr>
												<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
													<p>Grade ≥3 non-hematologic toxicity (if persisting despite optimal
                                                        medical treatment)</p>
												</td>
												<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
													<p>Withhold until symptoms resolve to:</p>
													<ul>
														<li>Grade ≤1;</li>
														<li>Grade ≤2 (if not considered a safety risk for the patient)
                                                        </li>
													</ul>
													<p>Resume at the <em>next lower dose</em>.</p>
												</td>
											</tr>
										</tbody>
									</table>
									<p>Permanently discontinue IBRANCE in patients with severe interstitial lung disease
                                        (ILD)/pneumonitis.</p>
									<p>Refer to the Full Prescribing Information for coadministered endocrine therapy
                                        dose adjustment guidelines in the event of toxicity and other relevant safety
                                        information or contraindications.</p>
								</div>
							</div>
						</text>
						<section id="43fbd4a1-8f15-4d65-a257-04df4a5741a3">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_459fbc93-4616-4552-9734-e5ca8265b9fc"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Dose Modifications for Use With Strong CYP3A Inhibitors</strong>
										</p>
										<p>Avoid concomitant use of strong CYP3A inhibitors and consider an alternative
                                            concomitant medication with no or minimal CYP3A inhibition. If patients must
                                            be coadministered a strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg
                                            once daily. If the strong inhibitor is discontinued, increase the IBRANCE
                                            dose (after 3 to 5 half-lives of the inhibitor) to the dose used prior to
                                            the initiation of the strong CYP3A inhibitor <em>[see <a href="#S7.1">Drug
                                                    Interactions (7.1)</a> and <a href="#ID_RefS12.3">Clinical
                                                    Pharmacology (12.3)</a>].</em></p>
									</div>
								</div>
							</text>
						</section>
						<section id="5125ae38-021b-4930-a204-3ec15bbe4a9e">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_6c05ea7d-9c8c-46a6-89e6-292c285845b2"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Dose Modifications for Hepatic Impairment</strong>
										</p>
										<p>No dose adjustment is required for patients with mild or moderate hepatic
                                            impairment (Child-Pugh classes A and B). For patients with severe hepatic
                                            impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg
                                            once daily for 21 consecutive days followed by 7 days off treatment to
                                            comprise a complete cycle of 28 days <em>[see <a href="#ID_RefS8.6">Use in
                                                    Specific Populations (8.6)</a> and <a href="#S12.3">Clinical
                                                    Pharmacology (12.3)</a>].</em></p>
									</div>
								</div>
							</text>
						</section>
					</section>
				</section>
				<section id="1c9f8e9c-ba81-4f80-9e65-5f72dacd6b82">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S3"/>
					</extension>
					<title value="3 DOSAGE FORMS AND STRENGTHS"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="43678-2"/>
							<display value="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<p>Capsules: 125 mg, 100 mg, and 75 mg. (<a href="#ID_RefS3">3</a>)</p>
							</div>
							<div style="narrative">
								<p>125 mg capsules: opaque, hard gelatin capsules, size 0, with caramel cap and body,
                                    printed with white ink "Pfizer" on the cap, "PBC 125" on the body.</p>
								<p>100 mg capsules: opaque,
                                        hard gelatin capsules, size 1, with caramel cap and light
                                        orange body, printed with white ink "Pfizer" on the cap, "PBC 100" on the
                                        body.</p>
								<p>75 mg capsules: opaque, hard gelatin capsules, size 2, with light orange cap and
                                    body, printed with white ink "Pfizer" on the cap, "PBC 75" on the body.</p>
							</div>
						</div>
					</text>
				</section>
				<section id="f062a2a0-4979-445b-ab97-489bb7a56663">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S4"/>
					</extension>
					<title value="4 CONTRAINDICATIONS"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34070-3"/>
							<display value="CONTRAINDICATIONS SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<p>None. (<a href="#ID_RefS4">4</a>)</p>
							</div>
							<div style="narrative">
								<p>None.</p>
							</div>
						</div>
					</text>
				</section>
				<section id="2a75ea96-3dff-46cb-a3f5-561ec51d0984">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2023-09-13"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S5"/>
					</extension>
					<title value="5 WARNINGS AND PRECAUTIONS"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="43685-7"/>
							<display value="WARNINGS AND PRECAUTIONS SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<ul>
									<li>Neutropenia: Monitor complete blood count prior to start of IBRANCE therapy and
                                        at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and
                                        as clinically indicated. (<a href="#ID_RefS2.2">2.2</a>, <a href="#ID_RefS5.1">5.1</a>)</li>
									<li>Interstitial Lung Disease (ILD)/Pneumonitis: Severe and fatal cases of
                                        ILD/pneumonitis have been reported. Monitor for pulmonary symptoms of
                                        ILD/pneumonitis. Interrupt IBRANCE immediately in patients with suspected
                                        ILD/pneumonitis. Permanently discontinue IBRANCE if severe ILD/pneumonitis
                                        occurs. (<a href="#ID_RefS5.2">5.2</a>)</li>
									<li>Embryo-Fetal Toxicity: IBRANCE can cause fetal harm. Advise patients of
                                        potential risk to a fetus and to use effective contraception. (<a href="#ID_RefS5.3">5.3</a>, <a href="#ID_RefS8.1">8.1</a>, <a href="#ID_RefS8.3">8.3</a>)</li>
								</ul>
							</div>
						</div>
					</text>
					<section id="29ff946d-9b22-49f2-a3ae-2474b1ce14c1">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S5.1"/>
						</extension>
						<title value="5.1Neutropenia"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Neutropenia was the most frequently reported adverse reaction in PALOMA-2 with an
                                        incidence of 80% and PALOMA-3 with an incidence of 83%. A Grade ≥3 decrease in
                                        neutrophil counts was reported in 66% of patients receiving IBRANCE plus
                                        letrozole in PALOMA-2 and 66% of patients receiving IBRANCE plus fulvestrant in
                                        PALOMA-3. In PALOMA-2 and PALOMA-3, the median time to first episode of any
                                        grade neutropenia was 15 days and the median duration of Grade ≥3 neutropenia
                                        was 7 days <em>[see <a href="#ID_RefS6.1">Adverse Reactions (6.1)</a>]</em>.
                                    </p>
									<p>Monitor complete blood counts prior to starting IBRANCE therapy and at the
                                        beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as
                                        clinically indicated. Dose interruption, dose reduction, or delay in starting
                                        treatment cycles is recommended for patients who develop Grade 3 or 4
                                        neutropenia <em>[see <a href="#ID_RefS2.2">Dosage and Administration
                                                (2.2)</a>]</em>. </p>
									<p>Febrile neutropenia has been reported in 1.8% of patients exposed to IBRANCE
                                        across PALOMA-2 and PALOMA-3. One death due to neutropenic sepsis was observed
                                        in PALOMA-3. Physicians should inform patients to promptly report any episodes
                                        of fever <em>[see <a href="#ID_RefS17">Patient Counseling Information
                                                (17)</a>]</em>. </p>
								</div>
							</div>
						</text>
					</section>
					<section id="6aca2a50-a8c7-4fb2-8f01-1755db6d35b1">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S5.2"/>
						</extension>
						<title value="5.2 Interstitial Lung Disease (ILD)/Pneumonitis"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or
                                        pneumonitis can occur in patients treated with cyclin-dependent kinase 4/6
                                        (CDK4/6) inhibitors, including IBRANCE when taken in combination with endocrine
                                        therapy.</p>
									<p>Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% of IBRANCE-treated
                                        patients had ILD/pneumonitis of any grade, 0.1% had Grade 3 or 4 and no fatal
                                        cases were reported. Additional cases of ILD/pneumonitis have been observed in
                                        the postmarketing setting, with fatalities reported <em>[see <a href="#ID_RefS6.2">Adverse Reactions (6.2)</a>]</em>.</p>
									<p>Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g.
                                        hypoxia, cough, dyspnea). In patients who have new or worsening respiratory
                                        symptoms and are suspected to have developed pneumonitis, interrupt IBRANCE
                                        immediately and evaluate the patient. Permanently discontinue IBRANCE in
                                        patients with severe ILD or pneumonitis <em>[see <a href="#ID_RefS2.2">Dosage
                                                and Administration (2.2)</a>]</em>.</p>
								</div>
							</div>
						</text>
					</section>
					<section id="d2c6581f-33fe-411a-aa00-3f4765cc7186">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S5.3"/>
						</extension>
						<title value="5.3Embryo-Fetal Toxicity"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Based on findings from animal studies and its mechanism of action, IBRANCE can
                                        cause fetal harm when administered to a pregnant woman. In animal reproduction
                                        studies, administration of palbociclib to pregnant rats and rabbits during
                                        organogenesis resulted in embryo-fetal toxicity at maternal exposures that were
                                        ≥4 times the human clinical exposure based on area under the curve (AUC). Advise
                                        pregnant women of the potential risk to a fetus. Advise females of reproductive
                                        potential to use effective contraception during treatment with IBRANCE and for
                                        at least 3 weeks after the last dose <em>[see <a href="#ID_RefS8.1">Use in
                                                Specific Populations (8.1</a> and <a href="#ID_RefS8.3">8.3)</a> and <a href="#ID_RefS12.1">Clinical Pharmacology (12.1)</a>]</em>. </p>
								</div>
							</div>
						</text>
					</section>
				</section>
				<section id="412ad9d8-24e7-4ebb-8989-b92e871b2fa6">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2023-09-13"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S6"/>
					</extension>
					<title value="6 ADVERSE REACTIONS"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34084-4"/>
							<display value="ADVERSE REACTIONS SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<p>Most common adverse reactions (incidence ≥10%) were neutropenia, infections,
                                    leukopenia, fatigue, nausea, stomatitis, anemia, alopecia, diarrhea,
                                    thrombocytopenia, rash, vomiting, decreased appetite, asthenia, and pyrexia. (<a href="#S6.2">6</a>)</p>
								<p>
									<strong>To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985
                                        or FDA at 1-800-FDA-1088 or <a href="https://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</strong>
								</p>
							</div>
							<div style="narrative">
								<p>The following clinically significant adverse reactions are described elsewhere in the
                                    labeling:</p>
								<ul>
									<li>Neutropenia <em>[see <a href="#ID_RefS5.1">Warnings and Precautions
                                                (5.1)</a>]</em></li>
									<li>ILD/Pneumonitis <em>[see <a href="#ID_RefS5.2">Warnings and Precautions
                                                (5.2)</a>]</em></li>
								</ul>
							</div>
						</div>
					</text>
					<section id="0a2d87af-130c-4e47-a33b-8f1bd869be51">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S6.1"/>
						</extension>
						<title value="6.1Clinical Studies Experience"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Because clinical trials are conducted under varying conditions, the adverse
                                        reaction rates observed cannot be directly compared to rates in other trials and
                                        may not reflect the rates observed in clinical practice.</p>
								</div>
							</div>
						</text>
						<section id="b19a4db3-a1bc-4925-85e4-501761575b5a">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2023-09-13"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_d20d9177-8d5e-4f9a-9ed9-99604e97ccf7"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p style="text-decoration: underline; ">
											<strong>PALOMA-2: IBRANCE plus
                                                Letrozole</strong>
										</p>
									</div>
								</div>
							</text>
							<section id="6c0a4e43-f583-4ac2-9f44-7564cbe66208">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2023-09-13"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_efd4058c-cf03-44c0-b548-6910f3cbe691"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>
												<strong>Patients with estrogen receptor (ER)-positive, HER2-negative
                                                    advanced or metastatic breast cancer for initial endocrine based
                                                    therapy</strong>
											</p>
											<p>The safety of IBRANCE (125 mg/day) plus letrozole (2.5 mg/day) versus
                                                placebo plus letrozole was evaluated in PALOMA-2. The data described
                                                below reflect exposure to IBRANCE in 444 out of 666 patients with
                                                ER-positive, HER2-negative advanced breast cancer who received at least
                                                1 dose of IBRANCE plus letrozole in PALOMA-2. The median duration of
                                                treatment for IBRANCE plus letrozole was 19.8 months while the median
                                                duration of treatment for placebo plus letrozole arm was 13.8 months.
                                            </p>
											<p>Dose reductions due to an adverse reaction of any grade occurred in 36%
                                                of patients receiving IBRANCE plus letrozole. No dose reduction was
                                                allowed for letrozole in PALOMA-2.</p>
											<p>Permanent discontinuation associated with an adverse reaction occurred in
                                                43 of 444 (9.7%) patients receiving IBRANCE plus letrozole and in 13 of
                                                222 (5.9%) patients receiving placebo plus letrozole. Adverse reactions
                                                leading to permanent discontinuation for patients receiving IBRANCE plus
                                                letrozole included neutropenia (1.1%) and alanine aminotransferase
                                                increase (0.7%).</p>
											<p>The most common adverse reactions (≥10%) of any grade reported in
                                                patients in the IBRANCE plus letrozole arm by descending frequency were
                                                neutropenia, infections, leukopenia, fatigue, nausea, alopecia,
                                                stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia,
                                                vomiting, decreased appetite, dry skin, pyrexia, and dysgeusia.</p>
											<p>The most frequently reported Grade ≥3 adverse reactions (≥5%) in patients
                                                receiving IBRANCE plus letrozole by descending frequency were
                                                neutropenia, leukopenia, infections, and anemia.</p>
											<p>Adverse reactions (≥10%) reported in patients who received IBRANCE plus
                                                letrozole or placebo plus letrozole in PALOMA-2 are listed in Table 4.
                                            </p>
											<table width="90%">
												<caption>Table 4. Adverse Reactions (≥10%) in PALOMA-2</caption>
												<colgroup span="7">
													<col width="33%"/>
													<col width="12%"/>
													<col width="10%"/>
													<col width="12%"/>
													<col width="11%"/>
													<col width="11%"/>
													<col width="11%"/>
												</colgroup>
												<thead>
													<tr>
														<td style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align=""/>
														<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>IBRANCE plus
                                                                Letrozole</strong>
															<br/>
															<strong>(N=444)</strong>
														</td>
														<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>Placebo plus
                                                                Letrozole</strong>
															<br/>
															<strong>(N=222)</strong>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; vertical-align: top; border-right: solid; border-left: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Adverse Reaction</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>All Grades</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 3</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 4</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>All Grades</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 3</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 4</strong>
															<br/>
															<strong>%</strong>
														</td>
													</tr>
												</thead>
												<tfoot>
													<tr>
														<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="7">Grading according to CTCAE
                                                            4.0.<br/>CTCAE=Common Terminology Criteria for Adverse
                                                            Events; N=number of patients; N/A=not applicable;</td>
													</tr>
												</tfoot>
												<tbody>
													<tr>
														<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
															<p>Infections and infestations</p>
														</td>
														<td colspan="3" style="text-align: left; border-right: solid; border-top: solid; border-bottom: solid; text-align: left; "/>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Infections<a href="#_RefID0ERKAG" id="ID0EZICK" name="foot-ref-_RefID0ERKAG">
																	<sup>2</sup>
																</a></p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">60<a href="#_RefID0EVKAG" id="ID0ESJCK" name="foot-ref-_RefID0EVKAG">
																	<sup>3</sup>
																</a></p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">6</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">42</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">3</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Blood and lymphatic system disorders</p>
														</td>
														<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Neutropenia</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">80</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">56</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">10</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">6</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Leukopenia</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">39</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">24</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Anemia</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">24</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">5</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">&lt;1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">9</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Thrombocytopenia</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">16</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">&lt;1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Metabolism and nutrition disorders</p>
														</td>
														<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Decreased appetite</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">15</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">9</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Nervous system disorders</p>
														</td>
														<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Dysgeusia</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">10</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">5</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Gastrointestinal disorders</p>
														</td>
														<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Stomatitis<a href="#_RefID0EBPAG" id="ID0ELKCK" name="foot-ref-_RefID0EBPAG">
																	<sup>4</sup>
																</a></p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">30</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">14</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Nausea</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">35</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">&lt;1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">26</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Diarrhea</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">26</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">19</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Vomiting</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">16</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">17</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Skin and subcutaneous tissue disorders</p>
														</td>
														<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Alopecia</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">33<a href="#_RefID0EKRAG" id="ID0EELCK" name="foot-ref-_RefID0EKRAG">
																	<sup>5</sup>
																</a></p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">N/A</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">N/A</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">16<a href="#_RefID0ESRAG" id="ID0E4LCK" name="foot-ref-_RefID0ESRAG">
																	<sup>6</sup>
																</a></p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">N/A</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">N/A</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Rash<a href="#_RefID0E2RAG" id="ID0EWMCK" name="foot-ref-_RefID0E2RAG">
																	<sup>7</sup>
																</a></p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">18</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">12</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Dry skin</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">12</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">6</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="4" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>General disorders and administration site conditions</p>
														</td>
														<td colspan="3" style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; "/>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Fatigue</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">37</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">28</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Asthenia</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">17</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">12</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
															<p>  Pyrexia</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">12</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">9</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
												</tbody>
											</table>
											<p><sup>
													<a name="_RefID0ERKAG" href="#foot-ref-_RefID0ERKAG">1</a>
												</sup>Infections includes all
                                                reported preferred terms (PTs) that are part of the System Organ Class
                                                Infections and infestations.</p>
											<p><sup>
													<a name="_RefID0EVKAG" href="#foot-ref-_RefID0EVKAG">2</a>
												</sup>Most
                                                common infections (≥1%) include: nasopharyngitis, upper respiratory
                                                tract infection, urinary tract infection, oral herpes, sinusitis,
                                                rhinitis, bronchitis, influenza, pneumonia, gastroenteritis,
                                                conjunctivitis, herpes zoster, pharyngitis, cellulitis, cystitis, lower
                                                respiratory tract infection, tooth infection, gingivitis, skin
                                                infection, gastroenteritis viral, respiratory tract infection,
                                                respiratory tract infection viral, and folliculitis.</p>
											<p><sup>
													<a name="_RefID0EBPAG" href="#foot-ref-_RefID0EBPAG">3</a>
												</sup>Stomatitis includes:
                                                aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth
                                                ulceration, mucosal inflammation, oral pain, oral discomfort,
                                                oropharyngeal pain, and stomatitis.</p>
											<p><sup>
													<a name="_RefID0EKRAG" href="#foot-ref-_RefID0EKRAG">4</a>
												</sup>Grade 1 events – 30%;
                                                Grade 2 events – 3%.</p>
											<p><sup>
													<a name="_RefID0ESRAG" href="#foot-ref-_RefID0ESRAG">5</a>
												</sup>Grade 1 events – 15%;
                                                Grade 2 events – 1%.</p>
											<p><sup>
													<a name="_RefID0E2RAG" href="#foot-ref-_RefID0E2RAG">6</a>
												</sup>Rash
                                                includes the following PTs: rash, rash maculo-papular, rash pruritic,
                                                rash erythematous, rash papular, dermatitis, dermatitis acneiform, and
                                                toxic skin eruption.</p>
											<p>Additional adverse reactions occurring at an overall incidence of
                                                &lt;10.0% of patients receiving IBRANCE plus letrozole in PALOMA-2
                                                included alanine aminotransferase increased (9.9%), aspartate
                                                aminotransferase increased (9.7%), epistaxis (9.2%), lacrimation
                                                increased (5.6%), dry eye (4.1%), vision blurred (3.6%), and febrile
                                                neutropenia (2.5%).</p>
											<table width="75%">
												<caption>Table 5. Laboratory Abnormalities in PALOMA-2</caption>
												<colgroup span="7">
													<col width="23%"/>
													<col width="11%"/>
													<col width="10%"/>
													<col width="11%"/>
													<col width="11%"/>
													<col width="10%"/>
													<col width="10%"/>
												</colgroup>
												<thead>
													<tr>
														<td style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align=""/>
														<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>IBRANCE plus
                                                                Letrozole</strong>
															<br/>
															<strong>(N=444)</strong>
														</td>
														<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>Placebo plus
                                                                Letrozole</strong>
															<br/>
															<strong>(N=222)</strong>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; vertical-align: top; border-right: solid; border-left: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Laboratory Abnormality</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>All Grades</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 3</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 4</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>All Grades</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 3</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 4</strong>
															<br/>
															<strong>%</strong>
														</td>
													</tr>
												</thead>
												<tfoot>
													<tr>
														<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="7">N=number of patients; WBC=white blood cells.
                                                        </td>
													</tr>
												</tfoot>
												<tbody>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
															<p>WBC decreased</p>
														</td>
														<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">97</p>
														</td>
														<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">35</p>
														</td>
														<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">25</p>
														</td>
														<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Neutrophils decreased</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">95</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">56</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">12</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">20</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Anemia</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">78</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">6</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">42</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Platelets decreased</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">63</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">14</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Aspartate aminotransferase increased</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">52</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">3</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">34</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
															<p>Alanine aminotransferase increased</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">43</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">&lt;1</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">30</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
												</tbody>
											</table>
										</div>
									</div>
								</text>
							</section>
						</section>
						<section id="7ea11c77-5b65-4c14-a315-719fe4d39ba9">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2023-09-13"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_b469161e-eaad-455a-822d-2f2b85b7c23b"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p style="text-decoration: underline; ">
											<strong>PALOMA-3: IBRANCE plus
                                                Fulvestrant</strong>
										</p>
									</div>
								</div>
							</text>
							<section id="61ef868c-e95a-4487-8e4a-50b116914d09">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2023-09-13"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_6c61fcfa-3484-4385-8d27-31b5bbf41ad4"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p>
												<strong>Patients with HR-positive, HER2-negative advanced or metastatic
                                                    breast cancer who have had disease progression on or after prior
                                                    adjuvant or metastatic endocrine therapy</strong>
											</p>
											<p>The safety of IBRANCE (125 mg/day) plus fulvestrant (500 mg) versus
                                                placebo plus fulvestrant was evaluated in PALOMA-3. The data described
                                                below reflect exposure to IBRANCE in 345 out of 517 patients with
                                                HR-positive, HER2-negative advanced or metastatic breast cancer who
                                                received at least 1 dose of IBRANCE plus fulvestrant in PALOMA-3. The
                                                median duration of treatment for IBRANCE plus fulvestrant was 10.8
                                                months while the median duration of treatment for placebo plus
                                                fulvestrant arm was 4.8 months.</p>
											<p>Dose reductions due to an adverse reaction of any grade occurred in 36%
                                                of patients receiving IBRANCE plus fulvestrant. No dose reduction was
                                                allowed for fulvestrant in PALOMA-3.</p>
											<p>Permanent discontinuation associated with an adverse reaction occurred in
                                                19 of 345 (6%) patients receiving IBRANCE plus fulvestrant, and in 6 of
                                                172 (3%) patients receiving placebo plus fulvestrant. Adverse reactions
                                                leading to discontinuation for those patients receiving IBRANCE plus
                                                fulvestrant included fatigue (0.6%), infections (0.6%), and
                                                thrombocytopenia (0.6%).</p>
											<p>The most common adverse reactions (≥10%) of any grade reported in
                                                patients in the IBRANCE plus fulvestrant arm by descending frequency
                                                were neutropenia, leukopenia, infections, fatigue, nausea, anemia,
                                                stomatitis, diarrhea, thrombocytopenia, vomiting, alopecia, rash,
                                                decreased appetite, and pyrexia.</p>
											<p>The most frequently reported Grade ≥3 adverse reactions (≥5%) in patients
                                                receiving IBRANCE plus fulvestrant in descending frequency were
                                                neutropenia and leukopenia.</p>
											<p>Adverse reactions (≥10%) reported in patients who received IBRANCE plus
                                                fulvestrant or placebo plus fulvestrant in PALOMA-3 are listed in Table
                                                6.</p>
											<table width="85%">
												<caption>Table 6. Adverse Reactions (≥10%) in PALOMA-3</caption>
												<colgroup span="7">
													<col width="23%"/>
													<col width="19%"/>
													<col width="16%"/>
													<col width="10%"/>
													<col width="11%"/>
													<col width="10%"/>
													<col width="10%"/>
												</colgroup>
												<thead>
													<tr>
														<td rowspan="3" style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>Adverse Reaction</strong>
														</td>
														<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>IBRANCE plus
                                                                Fulvestrant</strong>
															<br/>
															<strong>(N=345)</strong>
														</td>
														<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>Placebo plus
                                                                Fulvestrant</strong>
															<br/>
															<strong>(N=172)</strong>
														</td>
													</tr>
													<tr>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>All Grades</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 3</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 4</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>All Grades</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 3</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 4</strong>
														</td>
													</tr>
													<tr>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>%</strong>
														</td>
													</tr>
												</thead>
												<tfoot>
													<tr>
														<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="7">Grading according to CTCAE
                                                            4.0.<br/>CTCAE=Common Terminology Criteria for Adverse
                                                            Events; N=number of patients; N/A=not applicable.</td>
													</tr>
												</tfoot>
												<tbody>
													<tr>
														<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
															<p>Infections and infestations</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Infections<a href="#_RefID0EK5AG" id="ID0E1DAM" name="foot-ref-_RefID0EK5AG">
																	<sup>2</sup>
																</a></p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">47<a href="#_RefID0EO5AG" id="ID0ETEAM" name="foot-ref-_RefID0EO5AG">
																	<sup>3</sup>
																</a></p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">3</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">31</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">3</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Blood and lymphatic system disorders</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Neutropenia</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">83</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">55</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">11</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">4</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Leukopenia</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">53</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">30</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">5</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Anemia</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">30</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">4</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">13</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Thrombocytopenia</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">23</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Metabolism and nutrition disorders</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Decreased appetite</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">16</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">8</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Gastrointestinal disorders</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Nausea</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">34</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">28</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Stomatitis<a href="#_RefID0EICBG" id="ID0EMFAM" name="foot-ref-_RefID0EICBG">
																	<sup>4</sup>
																</a></p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">28</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">13</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Diarrhea</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">24</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">19</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Vomiting</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">19</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">15</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Skin and subcutaneous tissue disorders</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Alopecia</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">18<a href="#_RefID0E6DBG" id="ID0EFGAM" name="foot-ref-_RefID0E6DBG">
																	<sup>5</sup>
																</a></p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">N/A</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">N/A</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">6<a href="#_RefID0EHEBG" id="ID0E5GAM" name="foot-ref-_RefID0EHEBG">
																	<sup>6</sup>
																</a></p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">N/A</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">N/A</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>  Rash<a href="#_RefID0EREBG" id="ID0EXHAM" name="foot-ref-_RefID0EREBG">
																	<sup>7</sup>
																</a></p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">17</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">6</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td colspan="7" style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>General disorders and administration site conditions</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; text-align: left; ">
															<p>  Fatigue</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">41</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">29</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
															<p>  Pyrexia</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">13</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">&lt;1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">5</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
												</tbody>
											</table>
											<p><sup>
													<a name="_RefID0EK5AG" href="#foot-ref-_RefID0EK5AG">1</a>
												</sup>Infections includes all
                                                reported preferred terms (PTs) that are part of the System Organ Class
                                                Infections and infestations.</p>
											<p><sup>
													<a name="_RefID0EO5AG" href="#foot-ref-_RefID0EO5AG">2</a>
												</sup>Most
                                                common infections (≥1%) include: nasopharyngitis, upper respiratory
                                                infection, urinary tract infection, bronchitis, rhinitis, influenza,
                                                conjunctivitis, sinusitis, pneumonia, cystitis, oral herpes, respiratory
                                                tract infection, gastroenteritis, tooth infection, pharyngitis, eye
                                                infection, herpes simplex, and paronychia.</p>
											<p><sup>
													<a name="_RefID0EICBG" href="#foot-ref-_RefID0EICBG">3</a>
												</sup>Stomatitis includes:
                                                aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth
                                                ulceration, mucosal inflammation, oral pain, oropharyngeal discomfort,
                                                oropharyngeal pain, stomatitis.</p>
											<p><sup>
													<a name="_RefID0E6DBG" href="#foot-ref-_RefID0E6DBG">4</a>
												</sup>Grade 1 events – 17%;
                                                Grade 2 events – 1%.</p>
											<p><sup>
													<a name="_RefID0EHEBG" href="#foot-ref-_RefID0EHEBG">5</a>
												</sup>Grade 1 events – 6%.
                                            </p>
											<p><sup>
													<a name="_RefID0EREBG" href="#foot-ref-_RefID0EREBG">6</a>
												</sup>Rash
                                                includes: rash, rash maculo-papular, rash pruritic, rash erythematous,
                                                rash papular, dermatitis, dermatitis acneiform, toxic skin eruption.</p>
											<p>Additional adverse reactions occurring at an overall incidence of
                                                &lt;10.0% of patients receiving IBRANCE plus fulvestrant in PALOMA-3
                                                included asthenia (7.5%), aspartate aminotransferase increased (7.5%),
                                                dysgeusia (6.7%), epistaxis (6.7%), lacrimation increased (6.4%), dry
                                                skin (6.1%), alanine aminotransferase increased (5.8%), vision blurred
                                                (5.8%), dry eye (3.8%), and febrile neutropenia (0.9%).</p>
											<table width="80%">
												<caption>Table 7. Laboratory Abnormalities in PALOMA-3</caption>
												<colgroup span="7">
													<col width="21%"/>
													<col width="17%"/>
													<col width="14%"/>
													<col width="10%"/>
													<col width="10%"/>
													<col width="10%"/>
													<col width="9%"/>
												</colgroup>
												<thead>
													<tr>
														<td rowspan="2" style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>Laboratory Abnormality</strong>
														</td>
														<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>IBRANCE plus
                                                                Fulvestrant</strong>
															<br/>
															<strong>(N=345)</strong>
														</td>
														<td colspan="3" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
															<strong>Placebo plus
                                                                Fulvestrant</strong>
															<br/>
															<strong>(N=172)</strong>
														</td>
													</tr>
													<tr>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>All Grades</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 3</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 4</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>All Grades</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 3</strong>
															<br/>
															<strong>%</strong>
														</td>
														<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
															<strong>Grade 4</strong>
															<br/>
															<strong>%</strong>
														</td>
													</tr>
												</thead>
												<tfoot>
													<tr>
														<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="7">N=number of patients; WBC=white blood cells.
                                                        </td>
													</tr>
												</tfoot>
												<tbody>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
															<p>WBC decreased</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">99</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">45</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">26</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Neutrophils decreased</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">96</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">56</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">11</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">14</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Anemia</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">78</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">3</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">40</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Platelets decreased</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">62</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">1</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">10</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
															<p>Aspartate aminotransferase increased </p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">43</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">4</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">48</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">4</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
													<tr>
														<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
															<p>Alanine aminotransferase increased</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">36</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">2</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">34</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
														<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
															<p style="text-align: center; ">0</p>
														</td>
													</tr>
												</tbody>
											</table>
										</div>
									</div>
								</text>
							</section>
						</section>
					</section>
					<section id="8ff1743c-7716-4dfd-9c7a-f8aeb81d29db">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S6.2"/>
						</extension>
						<title value="6.2Postmarketing Experience"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>The following adverse reactions have been identified during post-approval use of
                                        IBRANCE. Because these reactions are reported voluntarily from a population of
                                        uncertain size, it is not always possible to reliably estimate their frequency
                                        or establish a causal relationship to drug exposure.</p>
									<p><em>Respiratory Disorders</em>: Interstitial lung disease (ILD)/non-infectious
                                        pneumonitis</p>
									<p><em>Skin and Subcutaneous Tissue Disorders:</em> Palmar-plantar
                                        erythrodysesthesia syndrome (PPES)</p>
								</div>
							</div>
						</text>
						<section id="dde5a6df-f7d5-41a1-959a-58d8fc82df52">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_abf81276-0bd9-4811-87b4-a175f89bbe36"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p style="text-decoration: underline; ">
											<strong>Male patients with HR-positive,
                                                HER2-negative advanced or metastatic breast cancer</strong>
										</p>
										<p>Based on limited data from postmarketing reports and electronic health
                                            records, the safety profile for men treated with IBRANCE is consistent with
                                            the safety profile in women treated with IBRANCE.</p>
									</div>
								</div>
							</text>
						</section>
					</section>
				</section>
				<section id="80ba5b55-6f05-4ac8-81a7-630988341a5d">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S7"/>
					</extension>
					<title value="7 DRUG INTERACTIONS"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34073-7"/>
							<display value="DRUG INTERACTIONS SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<ul>
									<li>CYP3A Inhibitors: Avoid concurrent use of IBRANCE with strong CYP3A inhibitors.
                                        If the strong inhibitor cannot be avoided, reduce the IBRANCE dose. (<a href="#ID_RefS2.2">2.2</a>, <a href="#ID_RefS7.1">7.1</a>) </li>
									<li>CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (<a href="#S7.2">7.2</a>)</li>
									<li>CYP3A Substrates: The dose of sensitive CYP3A4 substrates with narrow
                                        therapeutic indices may need to be reduced when given concurrently with IBRANCE.
                                        (<a href="#ID_RefS7.3">7.3</a>)</li>
								</ul>
							</div>
							<div style="narrative">
								<p>Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme
                                    SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of CYP3A.</p>
							</div>
						</div>
					</text>
					<section id="467df45f-cc69-4bda-a347-381ded5e31da">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S7.1"/>
						</extension>
						<title value="7.1Agents That May Increase Palbociclib Plasma Concentrations"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<section id="62515dd1-5290-44e1-af77-01aaae31bad3">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_4acec7b7-c8f0-40d0-8733-3d23640ecdbe"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Effect of CYP3A Inhibitors</strong>
										</p>
										<p>Coadministration of a strong CYP3A inhibitor (itraconazole) increased the
                                            plasma exposure of palbociclib in healthy subjects by 87%. Avoid concomitant
                                            use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir,
                                            itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir,
                                            posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and
                                            voriconazole). Avoid grapefruit or grapefruit juice during IBRANCE
                                            treatment. If coadministration of IBRANCE with a strong CYP3A inhibitor
                                            cannot be avoided, reduce the dose of IBRANCE <em>[see <a href="#ID_RefS2.2">Dosage and Administration (2.2)</a> and <a href="#ID_RefS12.3">Clinical Pharmacology (12.3)</a>]</em>.</p>
									</div>
								</div>
							</text>
						</section>
					</section>
					<section id="c1a668f3-bcb1-42db-99dd-4e7044442fd3">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S7.2"/>
						</extension>
						<title value="7.2Agents That May Decrease Palbociclib Plasma Concentrations"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<section id="2d061397-9dd2-44d5-bba0-d8a7129e69c7">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_d47a285c-2857-43b9-9a10-7e85f60647b7"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Effect of CYP3A Inducers</strong>
										</p>
										<p>Coadministration of a strong CYP3A inducer (rifampin) decreased the plasma
                                            exposure of palbociclib in healthy subjects by 85%. Avoid concomitant use of
                                            strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine,
                                            enzalutamide, and St John's Wort) <em>[see <a href="#ID_RefS12.3">Clinical
                                                    Pharmacology (12.3)</a>]</em>.</p>
									</div>
								</div>
							</text>
						</section>
					</section>
					<section id="ff17e88b-6dc3-4a65-a7c6-a168dd4be175">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S7.3"/>
						</extension>
						<title value="7.3Drugs That May Have Their Plasma Concentrations Altered by Palbociclib"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Coadministration of midazolam with multiple doses of IBRANCE increased the
                                        midazolam plasma exposure by 61%, in healthy subjects, compared to
                                        administration of midazolam alone. The dose of the sensitive CYP3A substrate
                                        with a narrow therapeutic index (e.g., alfentanil, cyclosporine,
                                        dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine,
                                        sirolimus, and tacrolimus) may need to be reduced, as IBRANCE may increase its
                                        exposure <em>[see <a href="#ID_RefS12.3">Clinical Pharmacology (12.3)</a>]</em>.
                                    </p>
								</div>
							</div>
						</text>
					</section>
				</section>
				<section id="30e4e134-5497-43b6-ae32-92558b6b22dc">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2023-09-13"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S8"/>
					</extension>
					<title value="8 USE IN SPECIFIC POPULATIONS"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="43684-0"/>
							<display value="USE IN SPECIFIC POPULATIONS SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="highlight">
								<ul>
									<li>Lactation: Advise not to breastfeed. (<a href="#ID_RefS8.2">8.2</a>)</li>
								</ul>
							</div>
						</div>
					</text>
					<section id="ee09c35f-ae11-4661-bb7b-88cfa4f5f312">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S8.1"/>
						</extension>
						<title value="8.1 Pregnancy"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42228-7"/>
								<display value="PREGNANCY SECTION"/>
							</coding></code>
						<section id="5f9422c2-0428-414a-81b1-900e3d4ac8b2">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_06a69bd8-7a6f-42ec-a7f7-8dbf8d035066"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Risk Summary</strong>
										</p>
										<p>Based on findings from animal studies and its mechanism of action, IBRANCE
                                            can cause fetal harm when administered to a pregnant woman <em>[see <a href="#ID_RefS12.1">Clinical Pharmacology (12.1)</a>]</em>. There
                                            are no available data in pregnant women to inform the drug-associated risk.
                                            In animal reproduction studies, administration of palbociclib to pregnant
                                            rats and rabbits during organogenesis resulted in embryo-fetal toxicity at
                                            maternal exposures that were ≥4 times the human clinical exposure based on
                                            AUC <em>[see </em><strong>Error! Hyperlink reference not
                                                valid.</strong><em>]</em>. Advise pregnant women of the potential risk
                                            to a fetus.</p>
										<p>The estimated background risk of major birth defects and miscarriage for the
                                            indicated population is unknown. In the U.S. general population, the
                                            estimated background risk of major birth defects and miscarriage in
                                            clinically recognized pregnancies is 2%–4% and 15%–20%, respectively.</p>
									</div>
								</div>
							</text>
						</section>
						<section id="fda29021-94b6-49e6-85dc-6c44bab15fc7">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="data"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Data</strong>
										</p>
									</div>
								</div>
							</text>
							<section id="201f84bf-75ab-48b0-8b9a-2905120d9a7c">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_c6c9776f-4031-40ab-b2b9-c04a52a24246"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p style="text-decoration: underline; ">Animal Data</p>
											<p>In a fertility and early embryonic development study in female rats,
                                                palbociclib was administered orally for 15 days before mating through to
                                                Day 7 of pregnancy, which did not cause embryo toxicity at doses up to
                                                300 mg/kg/day with maternal systemic exposures approximately 4 times the
                                                human exposure (AUC) at the recommended dose.</p>
											<p>In embryo-fetal development studies in rats and rabbits, pregnant animals
                                                received oral doses of palbociclib up to 300 mg/kg/day and 20 mg/kg/day,
                                                respectively, during the period of organogenesis. The maternally toxic
                                                dose of 300 mg/kg/day was fetotoxic in rats, resulting in reduced fetal
                                                body weights. At doses ≥100 mg/kg/day in rats, there was an increased
                                                incidence of a skeletal variation (increased incidence of a rib present
                                                at the seventh cervical vertebra). At the maternally toxic dose of 20
                                                mg/kg/day in rabbits, there was an increased incidence of skeletal
                                                variations, including small phalanges in the forelimb. At 300 mg/kg/day
                                                in rats and 20 mg/kg/day in rabbits, the maternal systemic exposures
                                                were approximately 4 and 9 times the human exposure (AUC) at the
                                                recommended dose, respectively.</p>
											<p>CDK4/6 double knockout mice have been reported to die in late stages of
                                                fetal development (gestation Day 14.5 until birth) due to severe anemia.
                                                However, knockout mouse data may not be predictive of effects in humans
                                                due to differences in degree of target inhibition.</p>
										</div>
									</div>
								</text>
							</section>
						</section>
					</section>
					<section id="560df3fe-329b-4817-87da-6727ebfbb101">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S8.2"/>
						</extension>
						<title value="8.2 Lactation"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="77290-5"/>
								<display value="LACTATION SECTION"/>
							</coding></code>
						<section id="2161f068-488f-4067-9ee9-5f77268aa131">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_2168b375-ad50-4d80-841a-b9c66b0bbda7"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Risk Summary</strong>
										</p>
										<p>There is no information regarding the presence of palbociclib in human milk,
                                            its effects on milk production, or the breastfed infant. Because of the
                                            potential for serious adverse reactions in breastfed infants from IBRANCE,
                                            advise a lactating woman not to breastfeed during treatment with IBRANCE and
                                            for 3 weeks after the last dose.</p>
									</div>
								</div>
							</text>
						</section>
					</section>
					<section id="206f2e51-f440-47f8-aa57-25a6aea8e761">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S8.3"/>
						</extension>
						<title value="8.3 Females and Males of Reproductive Potential"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="77291-3"/>
								<display value="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
							</coding></code>
						<section id="7214e588-c105-4832-9887-95dc223c499d">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_13c0e7c5-cec6-42fc-bf1f-1b7e5467954d"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Pregnancy Testing</strong>
										</p>
										<p>Based on animal studies, IBRANCE can cause fetal harm when administered to a
                                            pregnant woman <em>[see <a href="#ID_RefS8.1">Use in Specific Populations
                                                    (8.1)]</a>. </em>Females of reproductive potential should have a
                                            pregnancy test prior to starting treatment with IBRANCE.</p>
									</div>
								</div>
							</text>
						</section>
						<section id="8769473a-c0f2-45a1-8070-b9d77ca8744b">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_cf0fe8a0-a761-4c54-804c-046b3560c0e6"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Contraception</strong>
										</p>
									</div>
								</div>
							</text>
							<section id="d8806170-92a6-4f54-ad0d-a00036483ce4">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_b8bf300f-da1c-4955-b9f8-132a01d91c3c"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p style="text-decoration: underline; ">Females</p>
											<p>IBRANCE can cause fetal harm when administered to a pregnant woman
                                                <em>[see <a href="#ID_RefS8.1">Use in Specific Populations
                                                        (8.1)</a>]</em>. Advise females of reproductive potential to use
                                                effective contraception during treatment with IBRANCE and for at least 3
                                                weeks after the last dose.
                                            </p>
										</div>
									</div>
								</text>
							</section>
							<section id="6788eb62-563b-448d-9c13-9ad97a6738ba">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_5426da22-7376-42ad-857b-054e1e60088d"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p style="text-decoration: underline; ">Males</p>
											<p>Because of the potential for genotoxicity, advise male patients with
                                                female partners of reproductive potential to use effective contraception
                                                during treatment with IBRANCE and for 3 months after the last dose
                                                <em>[see <a href="#ID_RefS13.1">Nonclinical Toxicology (13.1)</a>]</em>.
                                            </p>
										</div>
									</div>
								</text>
							</section>
						</section>
						<section id="31204452-26e7-404d-81e4-09f7f3e7a47a">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_f6755e3a-700f-4ee3-834b-c4aed1b205ec"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Infertility</strong>
										</p>
									</div>
								</div>
							</text>
							<section id="dae0da06-a9dc-4e80-9df2-a095a86ced08">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_9616fe8b-dd4b-401b-8384-4a7ab2778efd"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p style="text-decoration: underline; ">Males</p>
											<p>Based on animal studies, IBRANCE may impair fertility in males of
                                                reproductive potential <em>[see <a href="#ID_RefS13.1">Nonclinical
                                                        Toxicology (13.1)</a>]</em>.</p>
										</div>
									</div>
								</text>
							</section>
						</section>
					</section>
					<section id="eb6f21a3-6662-4d0d-a39a-c6d4835af455">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S8.4"/>
						</extension>
						<title value="8.4 Pediatric Use"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="34081-0"/>
								<display value="PEDIATRIC USE SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>The safety and efficacy of IBRANCE in pediatric patients have not been studied.
                                    </p>
									<p>Altered glucose metabolism (glycosuria, hyperglycemia, decreased insulin)
                                        associated with changes in the pancreas (islet cell vacuolation), eye
                                        (cataracts, lens degeneration), kidney (tubule vacuolation, chronic progressive
                                        nephropathy) and adipose tissue (atrophy) were identified in a 27 week
                                        repeat-dose toxicology study in rats that were immature at the beginning of the
                                        studies and were most prevalent in males at oral palbociclib doses ≥30 mg/kg/day
                                        (approximately 11 times the adult human exposure [AUC] at the recommended dose).
                                        Some of these findings (glycosuria/hyperglycemia, pancreatic islet cell
                                        vacuolation, and kidney tubule vacuolation) were present with lower incidence
                                        and severity in a 15 week repeat-dose toxicology study in immature rats. Altered
                                        glucose metabolism or associated changes in the pancreas, eye, kidney and
                                        adipose tissue were not identified in a 27-week repeat-dose toxicology study in
                                        rats that were mature at the beginning of the study and in dogs in repeat-dose
                                        toxicology studies up to 39 weeks duration.</p>
									<p>Toxicities in teeth independent of altered glucose metabolism were observed in
                                        rats. Administration of 100 mg/kg palbociclib for 27 weeks (approximately 15
                                        times the adult human exposure [AUC] at the recommended dose) resulted in
                                        abnormalities in growing incisor teeth (discolored, ameloblast
                                        degeneration/necrosis, mononuclear cell infiltrate). Other toxicities of
                                        potential concern to pediatric patients have not been evaluated in juvenile
                                        animals.</p>
								</div>
							</div>
						</text>
					</section>
					<section id="5040a367-697e-43df-bab7-11bbefd3546f">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S8.5"/>
						</extension>
						<title value="8.5 Geriatric Use"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="34082-8"/>
								<display value="GERIATRIC USE SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Of 444 patients who received IBRANCE in PALOMA-2, 181 patients (41%) were ≥65
                                        years of age and 48 patients (11%) were ≥75 years of age. Of 347 patients who
                                        received IBRANCE in PALOMA-3, 86 patients (25%) were ≥65 years of age and 27
                                        patients (8%) were ≥75 years of age. No overall differences in safety or
                                        effectiveness of IBRANCE were observed between these patients and younger
                                        patients.</p>
								</div>
							</div>
						</text>
					</section>
					<section id="627a5424-4358-4f07-9854-5966e895b741">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S8.6"/>
						</extension>
						<title value="8.6Hepatic Impairment"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>No dose adjustment is required in patients with mild or moderate hepatic
                                        impairment (Child-Pugh classes A and B). For patients with severe hepatic
                                        impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg once
                                        daily for 21 consecutive days followed by 7 days off treatment to comprise a
                                        complete cycle of 28 days <em>[see <a href="#ID_RefS2.2">Dosage and
                                                Administration (2.2)</a>]</em>. Based on a pharmacokinetic trial in
                                        subjects with varying degrees of hepatic function, the palbociclib unbound
                                        exposure (unbound AUC<sub>INF</sub>) decreased by 17% in subjects with mild
                                        hepatic impairment (Child-Pugh class A), and increased by 34% and 77% in
                                        subjects with moderate (Child-Pugh class B) and severe (Child-Pugh class C)
                                        hepatic impairment, respectively, relative to subjects with normal hepatic
                                        function. Peak palbociclib unbound exposure (unbound C<sub>max</sub>) increased
                                        by 7%, 38% and 72% for mild, moderate and severe hepatic impairment,
                                        respectively, relative to subjects with normal hepatic function <em>[see <a href="#ID_RefS12.3">Clinical Pharmacology (12.3)</a>]</em>. </p>
									<p>Review the Full Prescribing Information for the aromatase inhibitor or
                                        fulvestrant for dose modifications related to hepatic impairment.</p>
								</div>
							</div>
						</text>
					</section>
					<section id="88abdb31-38bb-4a5d-a2a2-baa086d359d8">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S8.7"/>
						</extension>
						<title value="8.7Renal Impairment"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>No dose adjustment is required in patients with mild, moderate, or severe renal
                                        impairment (CrCl &gt;15 mL/min). Based on a pharmacokinetic trial in subjects
                                        with varying degrees of renal function, the total palbociclib exposure
                                        (AUC<sub>INF</sub>) increased by 39%, 42%, and 31% with mild (60 mL/min ≤ CrCl
                                        &lt;90 mL/min), moderate (30 mL/min ≤ CrCl &lt;60 mL/min), and severe (CrCl
                                        &lt;30 mL/min) renal impairment, respectively, relative to subjects with normal
                                        renal function. Peak palbociclib exposure (C<sub>max</sub>) increased by 17%,
                                        12%, and 15% for mild, moderate, and severe renal impairment, respectively,
                                        relative to subjects with normal renal function. The pharmacokinetics of
                                        palbociclib have not been studied in patients requiring hemodialysis <em>[see <a href="#ID_RefS12.3">Clinical Pharmacology (12.3)</a>]</em>.</p>
								</div>
							</div>
						</text>
					</section>
				</section>
				<section id="309b85d0-8834-4f8f-a1d0-9f94ed229fea">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S10"/>
					</extension>
					<title value="10 OVERDOSAGE"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34088-5"/>
							<display value="OVERDOSAGE SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="narrative">
								<p>There is no known antidote for IBRANCE. The treatment of overdose of IBRANCE should
                                    consist of general supportive measures.</p>
							</div>
						</div>
					</text>
				</section>
				<section id="c3c232cd-fd32-4ddb-a914-f2517a7bb300">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S11"/>
					</extension>
					<title value="11 DESCRIPTION"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34089-3"/>
							<display value="DESCRIPTION SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="narrative">
								<p>IBRANCE capsules for oral administration contain 125 mg, 100 mg, or 75 mg of
                                    palbociclib, a kinase inhibitor. The molecular formula for palbociclib is
                                    C<sub>24</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub>. The molecular weight is
                                    447.54 daltons. The chemical name is
                                    6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-<em>d</em>]pyrimidin-7(8<em>H</em>)-one,
                                    and its structural formula is:</p>
								<img src="#ibrance-01" alt="Chemical Structure"/>
								<p>Palbociclib is a yellow to orange powder with pKa of 7.4 (the secondary piperazine
                                    nitrogen) and 3.9 (the pyridine nitrogen). At or below pH 4, palbociclib behaves as
                                    a high-solubility compound. Above pH 4, the solubility of the drug substance reduces
                                    significantly.</p>
								<p><em>Inactive ingredients:</em> Microcrystalline cellulose, lactose monohydrate,
                                    sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard
                                    gelatin capsule shells. The light orange, light orange/caramel, and caramel opaque
                                    capsule shells contain gelatin, red iron oxide, yellow iron oxide, and titanium
                                    dioxide; the printing ink contains shellac, titanium dioxide, ammonium hydroxide,
                                    propylene glycol, and simethicone.</p>
							</div>
						</div>
					</text>
				</section>
				<section id="3f22add8-2f87-490a-894c-dae72f7769d8">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2023-09-13"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S12"/>
					</extension>
					<title value="12 CLINICAL PHARMACOLOGY"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34090-1"/>
							<display value="CLINICAL PHARMACOLOGY SECTION"/>
						</coding></code>
					<section id="d20291d2-96c9-4e20-91df-fd4812dab1f7">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S12.1"/>
						</extension>
						<title value="12.1 Mechanism of Action"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="43679-0"/>
								<display value="MECHANISM OF ACTION SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1
                                        and CDK4/6 are downstream of signaling pathways which lead to cellular
                                        proliferation. In vitro, palbociclib reduced cellular proliferation of estrogen
                                        receptor (ER)-positive breast cancer cell lines by blocking progression of the
                                        cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell
                                        lines with the combination of palbociclib and antiestrogens leads to decreased
                                        retinoblastoma (Rb) protein phosphorylation resulting in reduced E2F expression
                                        and signaling, and increased growth arrest compared to treatment with each drug
                                        alone. In vitro treatment of ER-positive breast cancer cell lines with the
                                        combination of palbociclib and antiestrogens led to increased cell senescence
                                        compared to each drug alone, which was sustained for up to 6 days following
                                        palbociclib removal and was greater if antiestrogen treatment was continued. In
                                        vivo studies using a patient-derived ER-positive breast cancer xenograft model
                                        demonstrated that the combination of palbociclib and letrozole increased the
                                        inhibition of Rb phosphorylation, downstream signaling, and tumor growth
                                        compared to each drug alone.</p>
									<p>Human bone marrow mononuclear cells treated with palbociclib in the presence or
                                        absence of an anti-estrogen in vitro did not become senescent and resumed
                                        proliferation following palbociclib withdrawal. </p>
								</div>
							</div>
						</text>
					</section>
					<section id="caac6a35-b69b-4ae9-a7a4-387b3c2c985c">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S12.2"/>
						</extension>
						<title value="12.2 Pharmacodynamics"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="43681-6"/>
								<display value="PHARMACODYNAMICS SECTION"/>
							</coding></code>
						<section id="e4781ae0-392c-4e39-8279-1dba4f42e322">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_64d039b9-ce29-4d8f-a9ac-456d11306b40"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Cardiac Electrophysiology</strong>
										</p>
										<p>The effect of palbociclib on the QT interval corrected for heart rate (QTc)
                                            was evaluated using time-matched electrocardiograms (ECGs) evaluating the
                                            change from baseline and corresponding pharmacokinetic data in 77 patients
                                            with breast cancer. Palbociclib had no large effect on QTc (i.e., &gt;20 ms)
                                            at 125 mg once daily for 21 consecutive days followed by 7 days off
                                            treatment to comprise a complete cycle of 28 days.</p>
									</div>
								</div>
							</text>
						</section>
					</section>
					<section id="2efd2763-57b8-4f1f-8c2a-69b4f529b7a7">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S12.3"/>
						</extension>
						<title value="12.3 Pharmacokinetics"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="43682-4"/>
								<display value="PHARMACOKINETICS SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>The pharmacokinetics (PK) of palbociclib were characterized in patients with
                                        solid tumors including advanced breast cancer and in healthy subjects.</p>
								</div>
							</div>
						</text>
						<section id="8ed8efc3-08db-454d-a11e-13fd194401d6">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_209dc345-a3ca-4466-9650-5c11a9a562d5"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Absorption</strong>
										</p>
										<p>The mean maximum observed concentration (C<sub>max</sub>) of palbociclib is
                                            generally observed between 6 to 12 hours (time to reach maximum
                                            concentration, T<sub>max</sub>) following oral administration. The mean
                                            absolute bioavailability of IBRANCE after an oral 125 mg dose is 46%. In the
                                            dosing range of 25 mg to 225 mg, the AUC and C<sub>max</sub> increased
                                            proportionally with dose in general. Steady state was achieved within 8 days
                                            following repeated once daily dosing. With repeated once daily
                                            administration, palbociclib accumulated with a median accumulation ratio of
                                            2.4 (range 1.5 to 4.2).</p>
									</div>
								</div>
							</text>
							<section id="8a57b379-acb6-455f-9f12-aecaec851f24">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_461235ab-ed6d-4f81-bb7d-bf506e23dee1"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><span style="text-decoration: underline; ">Food effect</span>:
                                                Palbociclib absorption and exposure were very low in approximately 13%
                                                of the population under the fasted condition. Food intake increased the
                                                palbociclib exposure in this small subset of the population, but did not
                                                alter palbociclib exposure in the rest of the population to a clinically
                                                relevant extent. Therefore, food intake reduced the intersubject
                                                variability of palbociclib exposure, which supports administration of
                                                IBRANCE with food. Compared to IBRANCE given under overnight fasted
                                                conditions, the population average area under the concentration-time
                                                curve from zero to infinity (AUC<sub>INF</sub>) and C<sub>max</sub> of
                                                palbociclib increased by 21% and 38%, respectively, when given with
                                                high-fat, high-calorie food (approximately 800 to 1000 calories with
                                                150, 250, and 500 to 600 calories from protein, carbohydrate, and fat,
                                                respectively), by 12% and 27%, respectively, when given with low-fat,
                                                low-calorie food (approximately 400 to 500 calories with 120, 250, and
                                                28 to 35 calories from protein, carbohydrate, and fat, respectively),
                                                and by 13% and 24%, respectively, when moderate-fat, standard calorie
                                                food (approximately 500 to 700 calories with 75 to 105, 250 to 350 and
                                                175 to 245 calories from protein, carbohydrate, and fat, respectively)
                                                was given 1 hour before and 2 hours after IBRANCE dosing.</p>
										</div>
									</div>
								</text>
							</section>
						</section>
						<section id="39ff054a-2533-4d2e-868b-ff94bf33136c">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_c1127bab-bbc2-484b-a04c-3c8213100f84"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Distribution</strong>
										</p>
										<p>Binding of palbociclib to human plasma proteins in vitro was approximately
                                            85%, with no concentration dependence over the concentration range of 500
                                            ng/mL to 5000 ng/mL. The mean fraction unbound (f<sub>u</sub>) of
                                            palbociclib in human plasma in vivo increased incrementally with worsening
                                            hepatic function. There was no obvious trend in the mean palbociclib
                                            f<sub>u</sub> in human plasma in vivo with worsening renal function. The
                                            geometric mean apparent volume of distribution (V<sub>z</sub>/F) was 2583 L
                                            with a coefficient of variation (CV) of 26%.</p>
									</div>
								</div>
							</text>
						</section>
						<section id="01b39606-1ff4-4f15-a8d3-f11b6536d21d">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_1914d8fc-3718-41ff-addd-896a2e9af177"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Metabolism</strong>
										</p>
										<p>In vitro and in vivo studies indicated that palbociclib undergoes hepatic
                                            metabolism in humans. Following oral administration of a single 125 mg dose
                                            of [<sup>14</sup>C]palbociclib to humans, the primary metabolic pathways for
                                            palbociclib involved oxidation and sulfonation, with acylation and
                                            glucuronidation contributing as minor pathways. Palbociclib was the major
                                            circulating drug-derived entity in plasma (23%). The major circulating
                                            metabolite was a glucuronide conjugate of palbociclib, although it only
                                            represented 1.5% of the administered dose in the excreta. Palbociclib was
                                            extensively metabolized with unchanged drug accounting for 2.3% and 6.9% of
                                            radioactivity in feces and urine, respectively. In feces, the sulfamic acid
                                            conjugate of palbociclib was the major drug-related component, accounting
                                            for 26% of the administered dose. In vitro studies with human hepatocytes,
                                            liver cytosolic and S9 fractions, and recombinant SULT enzymes indicated
                                            that CYP3A and SULT2A1 are mainly involved in the metabolism of palbociclib.
                                        </p>
									</div>
								</div>
							</text>
						</section>
						<section id="eaa1c656-3835-46a6-871d-0d4d2dabf29f">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_a7a11be4-9624-4acc-b4ba-f156a7b9c03b"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Elimination</strong>
										</p>
										<p>The geometric mean apparent oral clearance (CL/F) of palbociclib was 63.1
                                            L/hr (29% CV), and the mean (± standard deviation) plasma elimination
                                            half-life was 29 (±5) hours in patients with advanced breast cancer. In 6
                                            healthy male subjects given a single oral dose of
                                            [<sup>14</sup>C]palbociclib, a median of 91.6% of the total administered
                                            radioactive dose was recovered in 15 days; feces (74.1% of dose) was the
                                            major route of excretion, with 17.5% of the dose recovered in urine. The
                                            majority of the material was excreted as metabolites.</p>
									</div>
								</div>
							</text>
						</section>
						<section id="f4ff6b82-4f8a-423b-b081-4d6e3c771aa8">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_50b4b27b-d9f0-4512-a09c-04ae58472bee"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Age, Gender, and Body Weight</strong>
										</p>
										<p>Based on a population pharmacokinetic analysis in 183 patients with cancer
                                            (50 male and 133 female patients, age range from 22 to 89 years, and body
                                            weight range from 37.9 to 123 kg), gender had no effect on the exposure of
                                            palbociclib, and age and body weight had no clinically important effect on
                                            the exposure of palbociclib.</p>
									</div>
								</div>
							</text>
						</section>
						<section id="20c1170b-b3f4-45dc-a742-e04f79180b06">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_c517fc4c-9c43-4f9d-bbad-42ed3980353b"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Pediatric Population</strong>
										</p>
										<p>Pharmacokinetics of IBRANCE have not been evaluated in patients &lt;18 years
                                            of age.</p>
									</div>
								</div>
							</text>
						</section>
						<section id="46a4b5c5-3ecf-4a4d-95c2-deef5438d5b5">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_c9a13c98-4536-4df3-8d89-6c4106837399"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Hepatic Impairment</strong>
										</p>
										<p>Data from a pharmacokinetic trial in subjects with varying degrees of hepatic
                                            impairment indicate that palbociclib unbound AUC<sub>INF</sub> decreased 17%
                                            in subjects with mild hepatic impairment (Child-Pugh class A), and increased
                                            by 34% and 77% in subjects with moderate (Child-Pugh class B) and severe
                                            (Child-Pugh class C) hepatic impairment, respectively, relative to subjects
                                            with normal hepatic function. Palbociclib unbound C<sub>max</sub> increased
                                            by 7%, 38% and 72% for mild, moderate and severe hepatic impairment,
                                            respectively, relative to subjects with normal hepatic function. In
                                            addition, based on a population pharmacokinetic analysis that included 183
                                            patients, where 40 patients had mild hepatic impairment based on National
                                            Cancer Institute (NCI) classification (total bilirubin ≤ ULN and AST &gt;
                                            ULN, or total bilirubin &gt;1.0 to 1.5 × ULN and any AST), mild hepatic
                                            impairment had no effect on the exposure of palbociclib, further supporting
                                            the findings from the dedicated hepatic impairment study.</p>
									</div>
								</div>
							</text>
						</section>
						<section id="bc29fe76-15b8-4f73-8e44-6c5d484c8770">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2022-12-16"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_d17364fa-90a8-496d-b56e-701ac3d16042"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Renal Impairment</strong>
										</p>
										<p>Data from a pharmacokinetic trial in subjects with varying degrees of renal
                                            impairment indicate that palbociclib AUC<sub>INF</sub> increased by 39%,
                                            42%, and 31% with mild (60 mL/min ≤ CrCl &lt; 90 mL/min), moderate (30
                                            mL/min ≤ CrCl &lt;60 mL/min), and severe (CrCl &lt;30 mL/min) renal
                                            impairment, respectively, relative to subjects with normal renal function.
                                            Peak palbociclib exposure (C<sub>max</sub>) increased by 17%, 12%, and 15%
                                            for mild, moderate, and severe renal impairment, respectively, relative to
                                            subjects with normal renal function. In addition, based on a population
                                            pharmacokinetic analysis that included 183 patients where 73 patients had
                                            mild renal impairment and 29 patients had moderate renal impairment, mild
                                            and moderate renal impairment had no effect on the exposure of palbociclib.
                                            The pharmacokinetics of palbociclib have not been studied in patients
                                            requiring hemodialysis.</p>
									</div>
								</div>
							</text>
						</section>
						<section id="0d47fca8-7f58-49a4-8398-bcfce834d1e2">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2023-09-13"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_c55398f6-62a6-4e9e-9c76-e3c66c2d4fa5"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Drug Interactions</strong>
										</p>
										<p>In vitro data indicate that CYP3A and SULT enzyme SULT2A1 are mainly involved
                                            in the metabolism of palbociclib. Palbociclib is a weak time-dependent
                                            inhibitor of CYP3A following daily 125 mg dosing to steady state in humans.
                                            In vitro, palbociclib is not an inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9,
                                            2C19, and 2D6, and is not an inducer of CYP1A2, 2B6, 2C8, and 3A4 at
                                            clinically relevant concentrations.</p>
									</div>
								</div>
							</text>
							<section id="e8322b7f-a4f9-4daf-aba4-e4f5e5ef2300">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_49529cb2-58c5-47d7-9e6a-4b6f43090191"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>CYP3A Inhibitors:</em> Data from a drug interaction trial in healthy
                                                subjects (N=12) indicate that coadministration of multiple 200 mg daily
                                                doses of itraconazole with a single 125 mg IBRANCE dose increased
                                                palbociclib AUC<sub>INF</sub> and the C<sub>max</sub> by approximately
                                                87% and 34%, respectively, relative to a single 125 mg IBRANCE dose
                                                given alone <em>[see <a href="#S7.1">Drug Interactions (7.1</a>)]</em>.
                                            </p>
										</div>
									</div>
								</text>
							</section>
							<section id="3a23b749-4d85-43c6-a895-ee146e7f0015">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_fcaee425-a0ce-49f2-971b-9c93fdfb064f"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>CYP3A Inducers:</em> Data from a drug interaction trial in healthy
                                                subjects (N=15) indicate that coadministration of multiple 600 mg daily
                                                doses of rifampin, a strong CYP3A inducer, with a single 125 mg IBRANCE
                                                dose decreased palbociclib AUC<sub>INF</sub> and C<sub>max</sub> by 85%
                                                and 70%, respectively, relative to a single 125 mg IBRANCE dose given
                                                alone. Data from a drug interaction trial in healthy subjects (N=14)
                                                indicate that coadministration of multiple 400 mg daily doses of
                                                modafinil, a moderate CYP3A inducer, with a single 125 mg IBRANCE dose
                                                decreased palbociclib AUC<sub>INF</sub> and C<sub>max</sub> by 32% and
                                                11%, respectively, relative to a single 125 mg IBRANCE dose given alone
                                                <em>[see <a href="#S7.2">Drug Interactions (7.2)</a>]</em>.
                                            </p>
										</div>
									</div>
								</text>
							</section>
							<section id="e53d9b50-9079-404d-93e8-8bc52258422d">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_3f1b74de-b2f9-4e5f-86ba-66f52fcd7435"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>CYP3A Substrates:</em> Palbociclib is a weak time-dependent inhibitor
                                                of CYP3A following daily 125 mg dosing to steady state in humans. In a
                                                drug interaction trial in healthy subjects (N=26), coadministration of
                                                midazolam with multiple doses of IBRANCE increased the midazolam
                                                AUC<sub>INF</sub> and the C<sub>max</sub> values by 61% and 37%,
                                                respectively, as compared to administration of midazolam alone <em>[see
                                                    <a href="#ID_RefS7.3">Drug Interactions (7.3)</a>]</em>.</p>
										</div>
									</div>
								</text>
							</section>
							<section id="5fae2928-b44b-4bb8-a2b2-e0c4be9bf5e5">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_63d0958e-7db5-43e8-a376-b7020777084d"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>Gastric pH Elevating Medications:</em> In a drug interaction trial in
                                                healthy subjects, coadministration of a single 125 mg dose of IBRANCE
                                                with multiple doses of the proton pump inhibitor (PPI) rabeprazole under
                                                fed conditions decreased palbociclib C<sub>max</sub> by 41%, but had
                                                limited impact on AUC<sub>INF</sub> (13% decrease), when compared to a
                                                single dose of IBRANCE administered alone. Given the reduced effect on
                                                gastric pH of H2-receptor antagonists and local antacids compared to
                                                PPIs, the effect of these classes of acid-reducing agents on palbociclib
                                                exposure under fed conditions is expected to be minimal. Under fed
                                                conditions there is no clinically relevant effect of PPIs, H2-receptor
                                                antagonists, or local antacids on palbociclib exposure. In another
                                                healthy subject study, coadministration of a single dose of IBRANCE with
                                                multiple doses of the PPI rabeprazole under fasted conditions decreased
                                                palbociclib AUC<sub>INF</sub> and C<sub>max</sub> by 62% and 80%,
                                                respectively, when compared to a single dose of IBRANCE administered
                                                alone.</p>
										</div>
									</div>
								</text>
							</section>
							<section id="cbf257e6-d7a6-4a7e-8221-61964f582b36">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_72a717cc-4787-4eb7-91eb-3eb2e727f0f5"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>Letrozole:</em> Data from a clinical trial in patients with breast
                                                cancer showed that there was no drug interaction between palbociclib and
                                                letrozole when the 2 drugs were coadministered.</p>
										</div>
									</div>
								</text>
							</section>
							<section id="94ec5ed2-24e6-4f6e-b326-4f9497a8af91">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_b7588562-0f32-4d51-9873-a9d2613983a9"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>Fulvestrant:</em> Data from a clinical trial in patients with breast
                                                cancer showed that there was no clinically relevant drug interaction
                                                between palbociclib and fulvestrant when the 2 drugs were
                                                coadministered.</p>
										</div>
									</div>
								</text>
							</section>
							<section id="1dfdbd72-6527-47eb-98e8-43268a652efb">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_1fc5b415-751c-48e6-ad14-4e1990bfaa30"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>Goserelin:</em> Data from a clinical trial in patients with breast
                                                cancer showed that there was no clinically relevant drug interaction
                                                between palbociclib and goserelin when the 2 drugs were coadministered.
                                            </p>
										</div>
									</div>
								</text>
							</section>
							<section id="eafa95f2-1e1c-4e9d-a591-d71add1d7a0e">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2023-09-13"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_22344c82-2c70-4578-abf5-6577d5a8999e"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>Anastrozole or Exemestane:</em> No clinical data are available to
                                                evaluate drug interactions between anastrozole or exemestane and
                                                palbociclib. A clinically significant drug interaction between
                                                anastrozole or exemestane and palbociclib is not expected based on
                                                analyses of the effects of anastrozole, exemestane and palbociclib on or
                                                by metabolic pathways or transporter systems. </p>
										</div>
									</div>
								</text>
							</section>
							<section id="590e27aa-fb95-4b9d-9b0b-2bd954ca367e">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_6e6a8663-a24b-4e09-bf86-1fb062a3459f"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>Effect of Palbociclib on Transporters:</em> In vitro evaluations
                                                indicated that palbociclib has a low potential to inhibit the activities
                                                of drug transporters organic anion transporter (OAT)1, OAT3, organic
                                                cation transporter (OCT)2, and organic anion transporting polypeptide
                                                (OATP)1B1, OATP1B3 at clinically relevant concentrations. In vitro,
                                                palbociclib has the potential to inhibit OCT1 at clinically relevant
                                                concentrations, as well as the potential to inhibit P-glycoprotein
                                                (P-gp) or breast cancer resistance protein (BCRP) in the
                                                gastrointestinal tract at the proposed dose.</p>
										</div>
									</div>
								</text>
							</section>
							<section id="953ac39b-d21b-4eb5-90da-b7df97de10dc">
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
									<valueDateTime value="2022-12-16"/>
								</extension>
								<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
									<valueString value="ID_f0a320aa-4bd1-458b-8d38-9a0959b7d97f"/>
								</extension>
								<code><coding>
										<system value="http://loinc.org"/>
										<code value="42229-5"/>
										<display value="SPL UNCLASSIFIED SECTION"/>
									</coding></code>
								<text>
									<status value="additional"/>
									<div xmlns="http://www.w3.org/1999/xhtml">
										<div style="narrative">
											<p><em>Effect of Transporters on Palbociclib:</em> Based on in vitro data,
                                                P-gp and BCRP mediated transport are unlikely to affect the extent of
                                                oral absorption of palbociclib at therapeutic doses.</p>
										</div>
									</div>
								</text>
							</section>
						</section>
					</section>
				</section>
				<section id="4228e56f-b41d-4fe2-8557-7ad91e941225">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S13"/>
					</extension>
					<title value="13 NONCLINICAL TOXICOLOGY"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="43680-8"/>
							<display value="NONCLINICAL TOXICOLOGY SECTION"/>
						</coding></code>
					<section id="4c2e5387-8460-41b4-be64-83e364eaa68c">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="S13.1"/>
						</extension>
						<title value="13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility"/>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="34083-6"/>
								<display value="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Palbociclib was assessed for carcinogenicity in a 6-month transgenic mouse study
                                        and in a 2-year rat study. Oral administration of palbociclib for 2 years
                                        resulted in an increased incidence of microglial cell tumors in the central
                                        nervous system of male rats at a dose of 30 mg/kg/day (approximately 8 times the
                                        human clinical exposure based on AUC). There were no neoplastic findings in
                                        female rats at doses up to 200 mg/kg/day (approximately 5 times the human
                                        clinical exposure based on AUC). Oral administration of palbociclib to male and
                                        female rasH2 transgenic mice for 6 months did not result in increased incidence
                                        of neoplasms at doses up to 60 mg/kg/day. </p>
									<p>Palbociclib was aneugenic in Chinese Hamster Ovary cells in vitro and in the bone
                                        marrow of male rats at doses ≥100 mg/kg/day for 3 weeks. Palbociclib was not
                                        mutagenic in an in vitro bacterial reverse mutation (Ames) assay and was not
                                        clastogenic in the in vitro human lymphocyte chromosome aberration assay.</p>
									<p>In a fertility study in female rats, palbociclib did not affect mating or
                                        fertility at any dose up to 300 mg/kg/day (approximately 4 times human clinical
                                        exposure based on AUC) and no adverse effects were observed in the female
                                        reproductive tissues in repeat-dose toxicity studies up to 300 mg/kg/day in the
                                        rat and 3 mg/kg/day in the dog (approximately 6 times and similar to human
                                        exposure [AUC], at the recommended dose, respectively).</p>
									<p>The adverse effects of palbociclib on male reproductive function and fertility
                                        were observed in the repeat-dose toxicology studies in rats and dogs and a male
                                        fertility study in rats. In repeat-dose toxicology studies, palbociclib-related
                                        findings in the testis, epididymis, prostate, and seminal vesicle at ≥30
                                        mg/kg/day in rats and ≥0.2 mg/kg/day in dogs included decreased organ weight,
                                        atrophy or degeneration, hypospermia, intratubular cellular debris, and
                                        decreased secretion. Partial reversibility of male reproductive organ effects
                                        was observed in the rat and dog following a 4- and 12-week non-dosing period,
                                        respectively. These doses in rats and dogs resulted in approximately ≥10 and 0.1
                                        times, respectively, the exposure [AUC] in humans at the recommended dose. In
                                        the fertility and early embryonic development study in male rats, palbociclib
                                        caused no effects on mating but resulted in a slight decrease in fertility in
                                        association with lower sperm motility and density at 100 mg/kg/day with
                                        projected exposure levels [AUC] of 20 times the exposure in humans at the
                                        recommended dose.</p>
								</div>
							</div>
						</text>
					</section>
				</section>
				<section id="c2d90216-4824-4206-b371-7043a5a6c5cb">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2023-09-13"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S14"/>
					</extension>
					<title value="14 CLINICAL STUDIES"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34092-7"/>
							<display value="CLINICAL STUDIES SECTION"/>
						</coding></code>
					<section id="c0d9c060-e256-441e-bc3a-52af1fca7394">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="ID_29bea950-7bcf-42e1-9949-707d585c16c2"/>
						</extension>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p style="text-decoration: underline; ">
										<strong>PALOMA-2: IBRANCE plus
                                            Letrozole</strong>
									</p>
								</div>
							</div>
						</text>
						<section id="7bb3e790-323e-43fb-b1c9-2264ad03243f">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2023-09-13"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_2ab9382f-1658-45a6-8a95-4066db0b92e3"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Patients with ER-positive, HER2-negative advanced or metastatic
                                                breast cancer for initial endocrine based therapy</strong>
										</p>
										<p>PALOMA-2 was an international, randomized, double-blind, parallel-group,
                                            multicenter study of IBRANCE plus letrozole versus placebo plus letrozole
                                            conducted in postmenopausal women with ER-positive, HER2-negative advanced
                                            breast cancer who had not received previous systemic treatment for their
                                            advanced disease. A total of 666 patients were randomized 2:1 to IBRANCE
                                            plus letrozole or placebo plus letrozole. Randomization was stratified by
                                            disease site (visceral versus non-visceral), disease-free interval (de novo
                                            metastatic versus ≤12 months from the end of adjuvant treatment to disease
                                            recurrence versus &gt;12 months from the end of adjuvant treatment to
                                            disease recurrence), and nature of prior (neo)adjuvant anticancer therapies
                                            (prior hormonal therapies versus no prior hormonal therapy). IBRANCE was
                                            given orally at a dose of 125 mg daily for 21 consecutive days followed by 7
                                            days off treatment. Patients received study treatment until objective
                                            disease progression, symptomatic deterioration, unacceptable toxicity,
                                            death, or withdrawal of consent, whichever occurred first. The major
                                            efficacy outcome of the study was investigator-assessed progression-free
                                            survival (PFS) evaluated according to Response Evaluation Criteria in Solid
                                            Tumors Version 1.1 (RECIST). Additional efficacy outcome measures were
                                            confirmed overall response rate (ORR) as assessed by the investigator
                                            according to RECIST Version 1.1 and overall survival (OS).</p>
										<p>Patients enrolled in this study had a median age of 62 years (range 28 to
                                            89). The majority of patients were White (78%), and most patients had an
                                            Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
                                            (98%). Forty-eight percent of patients had received chemotherapy and 56% had
                                            received antihormonal therapy in the neoadjuvant or adjuvant setting prior
                                            to their diagnosis of advanced breast cancer. Thirty-seven percent of
                                            patients had no prior systemic therapy in the neoadjuvant or adjuvant
                                            setting. The majority of patients (97%) had metastatic disease. Twenty-three
                                            percent of patients had bone only disease, and 49% of patients had visceral
                                            disease.</p>
										<p>Major efficacy results from PALOMA-2 are summarized in Table 8 and Figure 1.
                                            Consistent results were observed across patient subgroups of disease-free
                                            interval (DFI), disease site, and prior therapy. The treatment effect of the
                                            combination on PFS was also supported by an independent review of
                                            radiographs. Based on the prespecified final OS analysis conducted after 435
                                            events, OS was not statistically significant.</p>
										<table width="80%">
											<caption>Table 8. Efficacy Results – PALOMA-2</caption>
											<colgroup span="3">
												<col width="40%"/>
												<col width="26%"/>
												<col width="26%"/>
											</colgroup>
											<thead>
												<tr>
													<td style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align=""/>
													<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
														<strong>IBRANCE plus Letrozole</strong>
													</td>
													<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
														<strong>Placebo plus Letrozole</strong>
													</td>
												</tr>
											</thead>
											<tfoot>
												<tr>
													<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="3">CI=confidence interval; ITT=Intent-to-Treat;
                                                        N=number of patients; NE=not estimable; OS=overall survival;
                                                        PFS=progression-free survival.</td>
												</tr>
											</tfoot>
											<tbody>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
														<p>
															<strong>Progression-free survival for ITT (investigator
                                                                assessment)</strong>
														</p>
													</td>
													<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=444</strong>
														</p>
													</td>
													<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=222</strong>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Number of PFS events (%)</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">194 (43.7)</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">137 (61.7)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Median progression-free survival (months, 95% CI)</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">24.8 (22.1, NE)</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">14.5 (12.9, 17.1)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Hazard ratio (95% CI) and p-value</p>
													</td>
													<td colspan="2" style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">0.576 (0.463, 0.718)<a href="#_Ref145336164" id="ID0ETIGM" name="foot-ref-_Ref145336164">
																<sup>2</sup>
															</a>,
                                                            p&lt;0.0001<a href="#_Ref145336182" id="ID0ERJGM" name="foot-ref-_Ref145336182">
																<sup>3</sup>
															</a></p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>
															<strong>Objective Response for patients with measurable
                                                                disease (investigator assessment)</strong>
														</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=338</strong>
														</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=171</strong>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Objective response rate<a href="#_RefID0EDSAI" id="ID0EPKGM" name="foot-ref-_RefID0EDSAI">
																<sup>4</sup>
															</a> (%, 95%
                                                            CI)</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">55.3 (49.9, 60.7)</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">44.4 (36.9, 52.2)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>
															<strong>Overall survival for ITT </strong>
														</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=444</strong>
														</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=222</strong>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Number of OS events (%) </p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">287 (64.6)</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">148 (66.7) </p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Median OS (months, 95% CI) </p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">53.8 (49.8, 59.2)</p>
													</td>
													<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">49.8 (42.3, 56.4)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
														<p>  Hazard ratio (95% CI) and p‑value </p>
													</td>
													<td colspan="2" style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">0.921 (0.755, 1.124)<a href="#_Ref145336164" id="ID0ETIGM" name="foot-ref-_Ref145336164">
																<sup>2</sup>
															</a>,
                                                            p=0.2087<a href="#_Ref145336182" id="ID0ERJGM" name="foot-ref-_Ref145336182">
																<sup>3</sup>
															</a></p>
													</td>
												</tr>
											</tbody>
										</table>
										<p><sup>
												<a name="_Ref145336164" href="#foot-ref-_Ref145336164">1</a>
											</sup>Cox
                                            proportional hazards model stratified by disease site (visceral vs.
                                            non-visceral) per randomization.</p>
										<p><sup>
												<a name="_Ref145336182" href="#foot-ref-_Ref145336182">2</a>
											</sup>Stratified log-rank test
                                            one-sided p-value.</p>
										<p><sup>
												<a name="_RefID0EDSAI" href="#foot-ref-_RefID0EDSAI">3</a>
											</sup>Response
                                            is based on confirmed responses.</p>
										<table width="100%">
											<colgroup span="1">
												<col width="100%"/>
											</colgroup>
											<tbody>
												<tr>
													<td style="text-align: center; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>Figure 1. Kaplan-Meier
                                                                Plot of Progression-Free Survival – PALOMA-2
                                                                (Investigator Assessment, Intent-to-Treat
                                                                Population)</strong>
															<br/>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: center; text-align: center; " align="center">
														<img src="#ibrance-02" alt="Figure 1"/>
														<p style="text-align: center; ">LET=letrozole; PAL=palbociclib;
                                                            PBO=placebo.</p>
													</td>
												</tr>
											</tbody>
										</table>
									</div>
								</div>
							</text>
						</section>
					</section>
					<section id="db06e919-8ce9-488b-b3b2-89aef9fb9799">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="ID_ff1dbb54-5d01-4a5a-9114-ed57a1228530"/>
						</extension>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p style="text-decoration: underline; ">
										<strong>PALOMA-3: IBRANCE plus
                                            Fulvestrant</strong>
									</p>
								</div>
							</div>
						</text>
						<section id="9df8e491-bd93-4bc9-bfd2-e09116da0793">
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
								<valueDateTime value="2023-09-13"/>
							</extension>
							<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
								<valueString value="ID_29c7f77b-b24d-4850-b048-9cc5c9a8fe67"/>
							</extension>
							<code><coding>
									<system value="http://loinc.org"/>
									<code value="42229-5"/>
									<display value="SPL UNCLASSIFIED SECTION"/>
								</coding></code>
							<text>
								<status value="additional"/>
								<div xmlns="http://www.w3.org/1999/xhtml">
									<div style="narrative">
										<p>
											<strong>Patients with HR-positive, HER2-negative advanced or metastatic
                                                breast cancer who have had disease progression on or after prior
                                                adjuvant or metastatic endocrine therapy</strong>
										</p>
										<p>PALOMA-3 was an international, randomized, double-blind, parallel group,
                                            multicenter study of IBRANCE plus fulvestrant versus placebo plus
                                            fulvestrant conducted in women with HR-positive, HER2-negative advanced
                                            breast cancer, regardless of their menopausal status, whose disease
                                            progressed on or after prior endocrine therapy. A total of 521
                                            pre/postmenopausal women were randomized 2:1 to IBRANCE plus fulvestrant or
                                            placebo plus fulvestrant and stratified by documented sensitivity to prior
                                            hormonal therapy, menopausal status at study entry (pre/peri versus
                                            postmenopausal), and presence of visceral metastases. IBRANCE was given
                                            orally at a dose of 125 mg daily for 21 consecutive days followed by 7 days
                                            off treatment. Pre/perimenopausal women were enrolled in the study and
                                            received the LHRH agonist goserelin for at least 4 weeks prior to and for
                                            the duration of PALOMA-3. Patients continued to receive assigned treatment
                                            until objective disease progression, symptomatic deterioration, unacceptable
                                            toxicity, death, or withdrawal of consent, whichever occurred first. The
                                            major efficacy outcome of the study was investigator-assessed PFS evaluated
                                            according to RECIST 1.1.</p>
										<p>Patients enrolled in this study had a median age of 57 years (range 29 to
                                            88). The majority of patients on study were White (74%), all patients had an
                                            ECOG PS of 0 or 1, and 80% were postmenopausal. All patients had received
                                            prior systemic therapy, and 75% of patients had received a previous
                                            chemotherapy regimen. Twenty-five percent of patients had received no prior
                                            therapy in the metastatic disease setting, 60% had visceral metastases, and
                                            23% had bone only disease.</p>
										<p>The results from the investigator-assessed PFS and final OS from PALOMA-3 are
                                            summarized in Table 9. The relevant Kaplan-Meier plots are shown in Figures
                                            2 and 3, respectively. Consistent PFS results were observed across patient
                                            subgroups of disease site, sensitivity to prior hormonal therapy, and
                                            menopausal status. After a median follow-up time of 45 months, the final OS
                                            results were not statistically significant.</p>
										<table width="80%">
											<caption>Table 9. Efficacy Results – PALOMA-3</caption>
											<colgroup span="3">
												<col width="40%"/>
												<col width="26%"/>
												<col width="26%"/>
											</colgroup>
											<thead>
												<tr>
													<td style="text-align: left; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align=""/>
													<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
														<strong>IBRANCE plus Fulvestrant</strong>
													</td>
													<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
														<strong>Placebo plus Fulvestrant</strong>
													</td>
												</tr>
											</thead>
											<tfoot>
												<tr>
													<td style="text-align: left; vertical-align: top; border-bottom: solid" colspan="3">CI=confidence interval; ITT=Intent-to-Treat;
                                                        N=number of patients; OS=overall survival; PFS=progression-free
                                                        survival.</td>
												</tr>
											</tfoot>
											<tbody>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
														<p>
															<strong>Progression-free survival for
                                                                ITT</strong>
															<br/>
															<strong>(investigator
                                                                assessment)</strong>
														</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=347</strong>
														</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=174</strong>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Number of PFS events (%)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">145 (41.8)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">114 (65.5)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Median PFS (months, 95% CI)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">9.5 (9.2, 11.0)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">4.6 (3.5, 5.6)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Hazard ratio (95% CI) and p-value</p>
													</td>
													<td colspan="2" style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">0.461 (0.360, 0.591),
                                                            p&lt;0.0001</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>
															<strong>Objective Response for patients with measurable
                                                                disease</strong>
															<br/>
															<strong>(investigator
                                                                assessment)</strong>
														</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=267</strong>
														</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=138</strong>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Objective response rate<a href="#_RefID0EDXAI" id="ID0EMXHM" name="foot-ref-_RefID0EDXAI">
																<sup>2</sup>
															</a> (%, 95%
                                                            CI)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">24.6 (19.6, 30.2)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">10.9 (6.2, 17.3)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>
															<strong>Overall survival for ITT </strong>
														</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=347</strong>
														</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>N=174</strong>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Number of OS events (%)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">201 (57.9)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">109 (62.6)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
														<p>  Median OS (months, 95% CI)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">34.9 (28.8, 40.0)</p>
													</td>
													<td style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">28.0 (23.6, 34.6)</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
														<p>  Hazard ratio (95% CI) and p-value</p>
													</td>
													<td colspan="2" style="text-align: center; vertical-align: middle; border-right: solid; border-bottom: solid; text-align: center; " align="center">
														<p style="text-align: center; ">0.814 (0.644, 1.029), p=0.0857<a href="#_RefID0EOYAI" id="ID0EFYHM" name="foot-ref-_RefID0EOYAI">
																<sup>3</sup>
															</a><a href="#_RefID0EPYAI" id="ID0E5YHM" name="foot-ref-_RefID0EPYAI">
																<sup>4</sup>
															</a></p>
													</td>
												</tr>
											</tbody>
										</table>
										<p><sup>
												<a name="_RefID0EDXAI" href="#foot-ref-_RefID0EDXAI">1</a>
											</sup>Responses are based on
                                            confirmed responses.</p>
										<p><sup>
												<a name="_RefID0EOYAI" href="#foot-ref-_RefID0EOYAI">2</a>
											</sup>Not
                                            statistically significant at the pre-specified 2-sided alpha level of 0.047.
                                        </p>
										<p><sup>
												<a name="_RefID0EPYAI" href="#foot-ref-_RefID0EPYAI">3</a>
											</sup>2-sided
                                            p-value from the log-rank test stratified by the presence of visceral
                                            metastases and sensitivity to prior endocrine therapy per randomization.</p>
										<table width="100%">
											<colgroup span="1">
												<col width="100%"/>
											</colgroup>
											<tbody>
												<tr>
													<td style="text-align: center; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>Figure 2. Kaplan-Meier
                                                                Plot of Progression-Free Survival – PALOMA-3
                                                                (Investigator Assessment, Intent-to-Treat Population)
                                                            </strong>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; text-align: left; ">
														<img src="#ibrance-03" alt="Figure 2"/>
													</td>
												</tr>
												<tr>
													<td style="text-align: center; text-align: center; " align="center">
														<p style="text-align: center; ">FUL=fulvestrant;
                                                            PAL=palbociclib; PBO=placebo.</p>
													</td>
												</tr>
											</tbody>
										</table>
										<table width="100%">
											<colgroup span="1">
												<col width="100%"/>
											</colgroup>
											<tbody>
												<tr>
													<td style="text-align: center; text-align: center; " align="center">
														<p style="text-align: center; ">
															<strong>Figure 3. Kaplan-Meier
                                                                Plot of Overall Survival (Intent-to-Treat Population) –
                                                                PALOMA-3</strong>
														</p>
													</td>
												</tr>
												<tr>
													<td style="text-align: left; text-align: left; ">
														<img src="#ibrance-04" alt="Figure 3"/>
													</td>
												</tr>
												<tr>
													<td style="text-align: center; text-align: center; " align="center">
														<p style="text-align: center; ">FUL=fulvestrant;
                                                            PAL=palbociclib; PBO=placebo.</p>
													</td>
												</tr>
											</tbody>
										</table>
									</div>
								</div>
							</text>
						</section>
					</section>
				</section>
				<section id="8fcab495-04e5-4543-b37c-72343608324b">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S16"/>
					</extension>
					<title value="16 HOW SUPPLIED/STORAGE AND HANDLING"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34069-5"/>
							<display value="HOW SUPPLIED SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="narrative">
								<p>IBRANCE is supplied in the following strengths and package configurations:</p>
								<table width="75%">
									<colgroup span="4">
										<col width="19%"/>
										<col width="18%"/>
										<col width="18%"/>
										<col width="32%"/>
									</colgroup>
									<thead>
										<tr>
											<td colspan="4" style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; border-left: solid; border-top: solid; text-align: center; font-weight: bold; " align="">
												<strong>IBRANCE Capsules</strong>
											</td>
										</tr>
										<tr>
											<td style="text-align: center; vertical-align: top; border-right: solid; border-left: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
												<strong>Package Configuration</strong>
											</td>
											<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
												<strong>Capsule Strength (mg)</strong>
											</td>
											<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
												<strong>NDC</strong>
											</td>
											<td style="text-align: center; vertical-align: top; border-right: solid; border-bottom: solid; text-align: center; font-weight: bold; " align="">
												<strong>Capsule Description</strong>
											</td>
										</tr>
									</thead>
									<tbody>
										<tr>
											<td style="text-align: left; border-right: solid; border-left: solid; border-top: solid; border-bottom: solid; text-align: left; ">
												<p>Bottles of 21 capsules</p>
											</td>
											<td style="text-align: center; border-right: solid; border-top: solid; border-bottom: solid; text-align: center; " align="center">
												<p style="text-align: center; ">125</p>
											</td>
											<td style="text-align: left; border-right: solid; border-top: solid; border-bottom: solid; text-align: left; ">
												<p>NDC 0069-0189-21</p>
											</td>
											<td style="text-align: left; border-right: solid; border-top: solid; border-bottom: solid; text-align: left; ">
												<p>opaque, hard gelatin capsules, size 0, with caramel cap and body,
                                                    printed with white ink "Pfizer" on the cap, "PBC 125" on the body
                                                </p>
											</td>
										</tr>
										<tr>
											<td style="text-align: left; border-right: solid; border-left: solid; border-bottom: solid; text-align: left; ">
												<p>Bottles of 21 capsules</p>
											</td>
											<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
												<p style="text-align: center; ">100</p>
											</td>
											<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
												<p>NDC 0069-0188-21</p>
											</td>
											<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
												<p>opaque, hard gelatin capsules, size 1, with caramel cap and light
                                                    orange body, printed with white ink "Pfizer" on the cap, "PBC 100"
                                                    on the body</p>
											</td>
										</tr>
										<tr>
											<td style="text-align: left; border-right: solid; border-bottom: solid; border-left: solid; text-align: left; ">
												<p>Bottles of 21 capsules</p>
											</td>
											<td style="text-align: center; border-right: solid; border-bottom: solid; text-align: center; " align="center">
												<p style="text-align: center; ">75</p>
											</td>
											<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
												<p>NDC 0069-0187-21</p>
											</td>
											<td style="text-align: left; border-right: solid; border-bottom: solid; text-align: left; ">
												<p>opaque, hard gelatin capsules, size 2, with light orange cap and
                                                    body, printed with white ink "Pfizer" on the cap, "PBC 75" on the
                                                    body</p>
											</td>
										</tr>
									</tbody>
								</table>
							</div>
						</div>
					</text>
					<section id="55cb2eff-8674-4120-a695-9bccc5108df0">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="ID_8d706147-d726-49bd-a7da-1fbbb568fac3"/>
						</extension>
						<code>
                            <coding>
								<system value="http://loinc.org"/>
								<code value="44425-7"/>
								<display value="STORAGE AND HANDLING SECTION"/>
							</coding>
                        </code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p>Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to
                                        30 °C (59 °F to 86 °F) <em>[see USP Controlled Room Temperature]</em>.</p>
								</div>
							</div>
						</text>
					</section>
				</section>
				<section id="e136306a-8b01-4e5f-a8ed-5e2b06c65bf6">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="S17"/>
					</extension>
					<title value="17 PATIENT COUNSELING INFORMATION"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="34076-0"/>
							<display value="INFORMATION FOR PATIENTS SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="narrative">
								<p>Advise the patient to read the FDA-approved patient labeling (Patient Information).
                                </p>
							</div>
						</div>
					</text>
					<section id="5ff5f17f-2b9c-4482-9ab7-aa03d4689546">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="ID_1a099017-6dc8-44e0-af70-fc88f31ead62"/>
						</extension>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p style="text-decoration: underline; ">Myelosuppression/Infection</p>
									<ul>
										<li>Advise patients to immediately report any signs or symptoms of
                                            myelosuppression or infection, such as fever, chills, dizziness, shortness
                                            of breath, weakness, or any increased tendency to bleed and/or to bruise
                                            <em>[see <a href="#ID_RefS5.1">Warnings and Precautions (5.1)</a>]</em>.
                                        </li>
									</ul>
								</div>
							</div>
						</text>
					</section>
					<section id="895558de-9304-4fe6-8a5e-50db0469e40f">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="ID_a7b6293a-387c-44c8-8ead-0e0ac64be7fa"/>
						</extension>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p style="text-decoration: underline; ">Interstitial Lung Disease/Pneumonitis</p>
									<ul>
										<li>Advise patients to immediately report new or worsening respiratory symptoms
                                            <em>[see <a href="#ID_RefS5.2">Warnings and Precautions (5.2)</a>]</em>.
                                        </li>
									</ul>
								</div>
							</div>
						</text>
					</section>
					<section id="f214d264-3c6a-401a-ad6b-76fb7200b23e">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="ID_af911acf-785f-42b3-9f00-cb3d7e10727c"/>
						</extension>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p style="text-decoration: underline; ">Drug Interactions</p>
									<ul>
										<li>Grapefruit may interact with IBRANCE. Patients should not consume grapefruit
                                            products while on treatment with IBRANCE.</li>
										<li>Inform patients to avoid strong CYP3A inhibitors and strong CYP3A inducers.
                                        </li>
										<li>Advise patients to inform their healthcare providers of all concomitant
                                            medications, including prescription medicines, over-the-counter drugs,
                                            vitamins, and herbal products <em>[see <a href="#S7.3">Drug Interactions
                                                    (7)</a>]</em>.</li>
									</ul>
								</div>
							</div>
						</text>
					</section>
					<section id="1fa3bf44-58c4-4368-b461-17814ecf47bb">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="ID_ff694ed3-9a30-49e2-b55a-c2d524650207"/>
						</extension>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p style="text-decoration: underline; ">Dosing and Administration</p>
									<ul>
										<li>Advise patients to take IBRANCE with food.</li>
										<li>If the patient vomits or misses a dose, an additional dose should not be
                                            taken. The next prescribed dose should be taken at the usual time. IBRANCE
                                            capsules should be swallowed whole (do not chew, crush, or open them prior
                                            to swallowing). No capsule should be ingested if it is broken, cracked, or
                                            otherwise not intact.</li>
										<li>Pre/perimenopausal women treated with IBRANCE should also be treated with
                                            LHRH agonists <em>[see <a href="#ID_RefS2.1">Dosage and Administration
                                                    (2.1)</a>]</em>.</li>
									</ul>
								</div>
							</div>
						</text>
					</section>
					<section id="e3c1b586-a6d8-4d21-8471-0106ace3b4df">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2022-12-16"/>
						</extension>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
							<valueString value="ID_22f0f644-1d0f-4247-97c9-baf21a95dfe7"/>
						</extension>
						<code><coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding></code>
						<text>
							<status value="additional"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<div style="narrative">
									<p style="text-decoration: underline; ">Pregnancy, Lactation, and Infertility</p>
									<ul>
										<li>Embryo-Fetal Toxicity<ul>
												<li>Advise females of reproductive potential of the potential risk to a
                                                    fetus and to use effective contraception during treatment with
                                                    IBRANCE therapy and for at least 3 weeks after the last dose. Advise
                                                    females to inform their healthcare provider of a known or suspected
                                                    pregnancy <em>[see <a href="#ID_RefS5.3">Warnings and Precautions
                                                            (5.3)</a> and <a href="#ID_RefS8.1">Use in Specific
                                                            Populations (8.1</a> and <a href="#ID_RefS8.3">8.3)</a>]</em>.</li>
												<li>Advise male patients with female partners of reproductive potential
                                                    to use effective contraception during treatment with IBRANCE and for
                                                    at least 3 months after the last dose <em>[see <a href="#ID_RefS8.3">Use in Specific Populations
                                                            (8.3)</a>].</em></li>
											</ul>
                                        </li>
										<li>Lactation: Advise women not to breastfeed during treatment with IBRANCE and
                                            for 3 weeks after the last dose <em>[see <a href="#ID_RefS8.2">Use in
                                                    Specific Populations (8.2)</a>].</em></li>
										<li>Infertility: Inform males of reproductive potential that IBRANCE may cause
                                            infertility and to consider sperm preservation before taking IBRANCE
                                            <em>[see <a href="#ID_RefS8.3">Use in Specific Populations (8.3)</a>]</em>.
                                        </li>
									</ul>
								</div>
							</div>
						</text>
					</section>
				</section>
				<section id="43098084-9d31-4740-8dbe-a8047dc93991">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2023-09-13"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="ID_f946f55b-354f-4a40-9285-42ca1b237573"/>
					</extension>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="42229-5"/>
							<display value="SPL UNCLASSIFIED SECTION"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="narrative">
								<p>This product's label may have been updated. For full prescribing information, please
                                    visit <a href="http://www.Pfizer.com">www.Pfizer.com</a>. For medical information
                                    about IBRANCE, please visit <a href="http://www.pfizermedinfo.com">www.pfizermedinfo.com</a> or call
                                    1-800-438-1985.</p>
								<img src="#ibrance-05" alt="Pfizer Logo 1"/>
								<p>LAB-0723-10.0</p>
							</div>
						</div>
					</text>
				</section>
				<section id="3fd15a64-1a72-42ca-ae98-634985054cc7">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2023-09-13"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="ID_6b75646a-2a17-41f0-972d-bf9a7bcc1e10"/>
					</extension>
					<title value="SPL PATIENT PACKAGE INSERT SECTION"/>
					<code>
						<coding>
							<system value="http://loinc.org"/>
							<code value="42230-3"/>
							<display value="SPL PATIENT PACKAGE INSERT SECTION"/>
						</coding>
					</code>
					<section>
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<id value="NESTED-SECTION-1"/>
						<title value="PATIENT INFORMATION"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
                                <b> IBRANCE <sup>®</sup> (EYE-brans) <br/> (palbociclib) </b>
                                <br/>
                                Tablets
                            </div>
						</text>
					</section>
					<section id="82a5a3bb-c2d4-4a6f-b911-abe9bc1a7c81">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<title value="What is the most important information I should know about IBRANCE?"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<p>
									<b>IBRANCE may cause serious side effects, including:</b>
								</p>
								<p>
                                    <b>Low white blood cell counts (neutropenia).</b> Low white
                                    blood cell counts are very common when taking IBRANCE and may
                                    cause serious infections that can lead to death. Your healthcare
                                    provider should check your white blood cell counts before and
                                    during treatment.
                                </p>
								<p>
                                    If you develop low white blood cell counts during treatment with
                                    IBRANCE, your healthcare provider may stop your treatment,
                                    decrease your dose, or may tell you to wait to begin your
                                    treatment cycle. Tell your healthcare provider right away if you
                                    have signs and symptoms of low white blood cell counts or
                                    infections such as fever and chills.
                                </p>
								<p>
                                    <b>Lung problems (pneumonitis).</b> IBRANCE may cause severe or
                                    life-threatening inflammation of the lungs during treatment that
                                    can lead to death. Tell your healthcare provider right away if
                                    you have any new or worsening symptoms, including:
                                </p>
								<ul>
									<li>chest pain</li>
									<li>cough with or without mucus</li>
									<li>trouble breathing or shortness of breath</li>
								</ul>
								<p>
                                    Your healthcare provider may interrupt or stop treatment with
                                    IBRANCE completely if your symptoms are severe.
                                </p>
								<p>
									<b> See <a href="">"What are the possible side effects of
                                            IBRANCE?"</a> for more information about side effects. </b>
								</p>
							</div>
						</text>
					</section>
					<section id="bd4efcd9-c565-4357-bd74-db65f8d9d2a8">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<id value="NESTED-SECTION-3"/>
						<title value="What is IBRANCE?"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<p>
                                    IBRANCE is a prescription medicine used in adults to treat
                                    hormone receptor (HR)-positive, human epidermal growth factor
                                    receptor 2 (HER2)-negative breast cancer that has spread to
                                    other parts of the body (metastatic) in combination with:
                                </p>
								<ul>
									<li>an aromatase inhibitor as the first hormonal based therapy
                                        in postmenopausal women or in men, or</li>
									<li>fulvestrant in people with disease progression following
                                        hormonal therapy.</li>
								</ul>
								<p>
                                    It is not known if IBRANCE is safe and effective in children.
                                </p>
							</div>
						</text>
					</section>
					<section id="8f1f3623-9f83-4e27-8d5a-1f0cc6a9d651">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<title value="Before taking IBRANCE, tell your healthcare provider about all of your medical conditions, including if you:"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<ul>
									<li>have fever, chills, or any other signs or symptoms of
                                        infection.</li>
									<li>have liver or kidney problems.</li>
									<li>are pregnant, or plan to become pregnant. IBRANCE can harm
                                        your unborn baby.</li>
									<li>
										<ul>
											<li>Females who are able to become pregnant should use
                                                effective birth control during treatment and for at
                                                least 3 weeks after the last dose of IBRANCE. Your
                                                healthcare provider may ask you to take a pregnancy
                                                test before you start treatment with IBRANCE.</li>
											<li>Males with female partners who can become pregnant
                                                should use effective birth control during treatment
                                                with IBRANCE for at least 3 months after the last
                                                dose of IBRANCE.</li>
											<li>Talk to your healthcare provider about birth control
                                                methods that may be right for you during this time.</li>
											<li>If you become pregnant or think you are pregnant,
                                                tell your healthcare provider right away.</li>
										</ul>
									</li>
									<li>are breastfeeding or plan to breastfeed. It is not known if
                                        IBRANCE passes into your breast milk. Do not breastfeed
                                        during treatment with IBRANCE and for 3 weeks after the last
                                        dose.</li>
								</ul>
								<p>
                                    <b>Tell your healthcare provider about all of the medicines you
                                        take, including</b> prescription and over-the-counter medicines,
                                    vitamins, and herbal supplements. IBRANCE and other medicines
                                    may affect each other causing side effects.
                                </p>
							</div>
						</text>
					</section>
					<section id="f323ca65-200c-4229-ba94-10852b0a2a11">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<title value="How should I take IBRANCE?"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<ul>
									<li>Take IBRANCE exactly as your healthcare provider tells you.</li>
									<li>IBRANCE tablets may be taken with or without food.</li>
									<li>IBRANCE should be taken at about the same time each day.</li>
									<li>Swallow IBRANCE tablets whole. Do not chew, crush or split
                                        IBRANCE tablets before swallowing them.</li>
									<li>Do not take any IBRANCE tablets that are broken, cracked, or
                                        that look damaged.</li>
									<li>Avoid grapefruit and grapefruit products during treatment
                                        with IBRANCE. Grapefruit may increase the amount of IBRANCE
                                        in your blood.</li>
									<li>Do not change your dose or stop taking IBRANCE unless your
                                        healthcare provider tells you.</li>
									<li>If you miss a dose of IBRANCE or vomit after taking a dose
                                        of IBRANCE, do not take another dose on that day. Take your
                                        next dose at your regular time.</li>
									<li>If you take too much IBRANCE, call your healthcare provider
                                        right away or go to the nearest hospital emergency room.</li>
								</ul>
							</div>
						</text>
					</section>
					<section id="4c58d3b9-16c5-45f8-bb9d-d40c59b8df76">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<title value="What are the possible side effects of IBRANCE?"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<p>
									<b> IBRANCE may cause serious side effects. See <a href="">"What
                                            is the most important information I should know about
                                            IBRANCE?"</a>
                                    </b>
								</p>
								<p>
									<b>The most common side effects of IBRANCE when used with either
                                        letrozole or fulvestrant include:</b>
								</p>
								<ul>
									<li> Low red blood cell counts and low platelet counts are
                                        common with IBRANCE. Call your healthcare provider right
                                        away if you develop any of these symptoms during treatment: <ul>
											<li>dizziness</li>
											<li>shortness of breath</li>
											<li>weakness</li>
											<li>bleeding or bruising more easily</li>
											<li>nosebleeds</li>
										</ul>
                                    </li>
									<li> infections (see <a href="">"What is the most important
                                            information I should know about IBRANCE?</a>") </li>
									<li>tiredness</li>
									<li>nausea</li>
									<li>sore mouth</li>
									<li>abnormalities in liver blood tests</li>
									<li>diarrhea</li>
									<li>hair thinning or hair loss</li>
									<li>vomiting</li>
									<li>rash</li>
									<li>loss of appetite</li>
								</ul>
								<p>
                                    IBRANCE may cause fertility problems in males. This may affect
                                    your ability to father a child. Talk to your healthcare provider
                                    about family planning options before starting IBRANCE if this is
                                    a concern for you.
                                </p>
								<p>
                                    These are not all of the possible side effects of IBRANCE.
                                </p>
								<p>
                                    Call your doctor for medical advice about side effects. You may
                                    report side effects to FDA at 1-800-FDA-1088.
                                </p>
							</div>
						</text>
					</section>
					<section id="a419819a-6d01-4a72-9564-3458a117c741">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<title value="How should I store IBRANCE?"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<ul>
									<li>Store IBRANCE at 68 °F to 77 °F (20 °C to 25 °C) in the
                                        original blister pack.</li>
								</ul>
								<p>
									<b>Keep IBRANCE and all medicines out of the reach of children.</b>
								</p>
							</div>
						</text>
					</section>
					<section id="0a3a2d68-6872-4ef9-b360-fe6741c9fcd4">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<title value="General information about the safe and effective use of IBRANCE"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<p>
                                    Medicines are sometimes prescribed for purposes other than those
                                    listed in a Patient Information leaflet. Do not use IBRANCE for
                                    a condition for which it was not prescribed. Do not give IBRANCE
                                    to other people, even if they have the same symptoms you have.
                                    It may harm them. You can ask your pharmacist or healthcare
                                    provider for more information about IBRANCE that is written for
                                    health professionals.
                                </p>
							</div>
						</text>
					</section>
					<section id="619ed04c-1aec-4749-8cf4-34b3f97e2d4f">
						<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
							<valueDateTime value="2023-09-13"/>
						</extension>
						<title value="What are the ingredients in IBRANCE?"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<text>
							<status value="generated"/>
							<div xmlns="http://www.w3.org/1999/xhtml">
								<p>
                                    Active ingredient: palbociclib
                                </p>
								<p>
                                    Inactive ingredients: microcrystalline cellulose, colloidal
                                    silicon dioxide, crospovidone, magnesium stearate, succinic
                                    acid, HPMC 2910/hypromellose, titanium dioxide, triacetin, and
                                    FD&amp;C Blue #2/Indigo Carmine Aluminum Lake. In addition, the
                                    75 mg and 125 mg tablets contain red iron oxide and the 100 mg
                                    tablets contain yellow iron oxide.
                                </p>
								<p>
									<img src="#ibrance-05" alt="Pfizer Logo test"/>
								</p>
								<p>
                                    LAB-1372-1.0
                                </p>
								<p>
                                    For more information, go to www.IBRANCE.com or call
                                    1-800-438-1985.
                                </p>
							</div>
						</text>
					</section>
				</section>
				<section id="b72a24fd-4e71-469c-9aa8-7f3613d1ea9c">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="ID_6640ddbd-9e6f-4e34-a48a-d0d4a14b80e0"/>
					</extension>
					<title value="PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label"/>
					<code>
                        <coding>
							<system value="http://loinc.org"/>
							<code value="51945-4"/>
							<display value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
						</coding>
                    </code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="narrative">
								<p>NDC 0069-0187-21</p>
								<p>
									<strong>
										<em>Pfizer</em>
									</strong>
								</p>
								<p>
									<strong>Ibrance</strong>
									<sup>®</sup>
									<br/>
									<strong>(palbociclib)</strong>
									<br/>
									<strong>capsules</strong>
								</p>
								<p>
									<strong>75 mg</strong>
								</p>
								<p>21 Capsules</p>
								<p>
									<strong>Rx only</strong>
								</p>
								<img src="#ibrance-07" alt="PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label"/>
							</div>
						</div>
					</text>
				</section>
				<section id="ff1b9268-8429-45f6-acf8-1cc52f63ea81">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="ID_92772f40-36b2-4483-9694-fd83bbcbd906"/>
					</extension>
					<title value="PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="51945-4"/>
							<display value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="narrative">
								<p>NDC 0069-0188-21</p>
								<p>
									<strong>
										<em>Pfizer</em>
									</strong>
								</p>
								<p>
									<strong>Ibrance</strong>
									<sup>®</sup>
									<br/>
									<strong>(palbociclib)</strong>
									<br/>
									<strong>capsules</strong>
								</p>
								<p>
									<strong>100 mg</strong>
								</p>
								<p>21 Capsules</p>
								<p>
									<strong>Rx only</strong>
								</p>
								<img src="#ibrance-08" alt="PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label"/>
							</div>
						</div>
					</text>
				</section>
				<section id="9cc58f8b-795a-43dc-a58a-226bccea0e32">
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
						<valueDateTime value="2022-12-16"/>
					</extension>
					<extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
						<valueString value="ID_b089e9cb-ee02-4eb4-bafe-4e06d8bd4bfc"/>
					</extension>
					<title value="PRINCIPAL DISPLAY PANEL - 125 mg Capsule Bottle Label"/>
					<code><coding>
							<system value="http://loinc.org"/>
							<code value="51945-4"/>
							<display value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
						</coding></code>
					<text>
						<status value="additional"/>
						<div xmlns="http://www.w3.org/1999/xhtml">
							<div style="narrative">
								<p>NDC 0069-0189-21</p>
								<p>
									<strong>
										<em>Pfizer</em>
									</strong>
								</p>
								<p>
									<strong>Ibrance</strong>
									<sup>®</sup>
									<br/>
									<strong>(palbociclib)</strong>
									<br/>
									<strong>capsules</strong>
								</p>
								<p>
									<strong>125 mg</strong>
								</p>
								<p>21 Capsules</p>
								<p>
									<strong>Rx only</strong>
								</p>
								<img src="#ibrance-09" alt="PRINCIPAL DISPLAY PANEL - 125 mg Capsule Bottle Label"/>
							</div>
						</div>
					</text>
				</section>
				<section id="eceba63e-59e8-49b9-bd20-510df0c31795">
					<text>
						<title value="Annotations"/>
						<code>
							<coding>
								<system value="http://loinc.org"/>
								<code value="42229-5"/>
								<display value="SPL UNCLASSIFIED SECTION"/>
							</coding>
						</code>
						<status value="additional"/>
						<div class="comments" xmlns="http://www.w3.org/1999/xhtml"/>
						<div class="trackChanges" xmlns="http://www.w3.org/1999/xhtml"></div>
					</text>
				</section>
			</Composition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Organization/134489525"/>
		<resource>
			<Organization>
				<id value="134489525"/>
				<meta>
					<profile value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedLabeler"/>
				</meta>
				<identifier>
					<system value="urn:oid:1.3.6.1.4.1.519.1"/>
					<value value="134489525"/>
				</identifier>
				<type>
					<coding>
						<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes"/>
						<code value="Labeler"/>
					</coding>
				</type>
				<name value="Pfizer Laboratories Div Pfizer Inc"/>
			</Organization>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Organization/618054084"/>
		<resource>
			<Organization>
				<id value="618054084"/>
				<meta>
					<profile value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedEstablishment"/>
				</meta>
				<identifier>
					<system value="urn:oid:1.3.6.1.4.1.519.1"/>
					<value value="618054084"/>
				</identifier>
				<type>
					<coding>
						<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes"/>
						<code value="Establishment"/>
					</coding>
				</type>
				<name value="Pharmacia &amp; Upjohn Company LLC (DUNS: 618054084)"/>
			</Organization>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Organization/985052076"/>
		<resource>
			<Organization>
				<id value="985052076"/>
				<meta>
					<profile value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedEstablishment"/>
				</meta>
				<identifier>
					<system value="urn:oid:1.3.6.1.4.1.519.1"/>
					<value value="985052076"/>
				</identifier>
				<type>
					<coding>
						<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes"/>
						<code value="Establishment"/>
					</coding>
				</type>
				<name value="Pfizer Ireland Pharmaceuticals (DUNS: 985052076)"/>
			</Organization>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Organization/341970073"/>
		<resource>
			<Organization>
				<id value="341970073"/>
				<meta>
					<profile value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedEstablishment"/>
				</meta>
				<identifier>
					<system value="urn:oid:1.3.6.1.4.1.519.1"/>
					<value value="341970073"/>
				</identifier>
				<type>
					<coding>
						<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes"/>
						<code value="Establishment"/>
					</coding>
				</type>
				<name value="Pfizer Manufacturing Deutschland GmbH (DUNS: 341970073)"/>
			</Organization>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Organization/936889401"/>
		<resource>
			<Organization>
				<id value="936889401"/>
				<meta>
					<profile value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedEstablishment"/>
				</meta>
				<identifier>
					<system value="urn:oid:1.3.6.1.4.1.519.1"/>
					<value value="936889401"/>
				</identifier>
				<type>
					<coding>
						<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes"/>
						<code value="Establishment"/>
					</coding>
				</type>
				<name value="Pfizer Asia Manufacturing Pte Ltd (DUNS: 936889401)"/>
			</Organization>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/LACTOSE_MONOHYDRATE"/>
		<resource>
			<Ingredient>
				<id value="LACTOSE_MONOHYDRATE"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="EWQ57Q8I5X"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="true"/>
				<substance>
					<code>
                    <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="EWQ57Q8I5X"/>
								<display value="LACTOSE MONOHYDRATE"/>
							</coding>
						</concept>
                </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/SODIUM_STARCH_GLYCOLATE_TYPE_A_POTATO"/>
		<resource>
			<Ingredient>
				<id value="SODIUM_STARCH_GLYCOLATE_TYPE_A_POTATO"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="5856J3G2A2"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                    <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="5856J3G2A2"/>
								<display value="SODIUM STARCH GLYCOLATE TYPE A POTATO"/>
							</coding>
						</concept>
                </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/GELATIN_UNSPECIFIED"/>
		<resource>
			<Ingredient>
				<id value="GELATIN_UNSPECIFIED"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="2G86QN327L"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="true"/>
				<substance>
					<code>
                    <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="2G86QN327L"/>
								<display value="GELATIN, UNSPECIFIED"/>
							</coding>
						</concept>
                </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/FERRIC_OXIDE_YELLOW"/>
		<resource>
			<Ingredient>
				<id value="FERRIC_OXIDE_YELLOW"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="EX438O2MRT"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                    <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="EX438O2MRT"/>
								<display value="FERRIC OXIDE YELLOW"/>
							</coding>
						</concept>
                </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/SHELLAC"/>
		<resource>
			<Ingredient>
				<id value="SHELLAC"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="46N107B71O"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                    <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="46N107B71O"/>
								<display value="SHELLAC"/>
							</coding>
						</concept>
                </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/AMMONIA"/>
		<resource>
			<Ingredient>
				<id value="AMMONIA"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="5138Q19F1X"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                    <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="5138Q19F1X"/>
								<display value="AMMONIA"/>
							</coding>
						</concept>
                </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/PROPYLENE_GLYCOL"/>
		<resource>
			<Ingredient>
				<id value="PROPYLENE_GLYCOL"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="6DC9Q167V3"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                    <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="6DC9Q167V3"/>
								<display value="PROPYLENE GLYCOL"/>
							</coding>
						</concept>
                </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/DIMETHICONE"/>
		<resource>
			<Ingredient>
				<id value="DIMETHICONE"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="92RU3N3Y1O"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                    <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="92RU3N3Y1O"/>
								<display value="DIMETHICONE"/>
							</coding>
						</concept>
                </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/FERRIC-OXIDE-RED"/>
		<resource>
			<Ingredient>
				<id value="FERRIC-OXIDE-RED"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="1K09F3G675"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                        <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="1K09F3G675"/>
								<display value="FERRIC OXIDE RED"/>
							</coding>
						</concept>
                    </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/MAGNESIUM-STEARATE"/>
		<resource>
			<Ingredient>
				<id value="MAGNESIUM-STEARATE"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="70097M6I30"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                        <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="70097M6I30"/>
								<display value="MAGNESIUM STEARATE"/>
							</coding>
						</concept>
                    </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/MICROCRYSTALLINE-CELLULOSE"/>
		<resource>
			<Ingredient>
				<id value="MICROCRYSTALLINE-CELLULOSE"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="OP1R32D61U"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                        <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="OP1R32D61U"/>
								<display value="MICROCRYSTALLINE CELLULOSE"/>
							</coding>
						</concept>
                    </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/palbociclib75"/>
		<resource>
			<Ingredient>
				<id value="palbociclib75"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="G9ZF61LE7G"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="ACTIB"/>
						<display value="active ingredient - basis of strength"/>
					</coding>
				</role>
				<group>
					<coding>
						<system value="http://ncimeta.nci.nih.gov"/>
						<code value="N0000175605"/>
						<display value="Kinase Inhibitor"/>
					</coding>
				</group>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                        <reference>
							<reference value="SubstanceDefinition/palbociclib"/>
						</reference>
                    </code>
					<strength>
						<presentationQuantity>
							<system value="http://unitsofmeasure.org"/>
							<value value="75"/>
							<unit value="mg"/>
							<code value="mg"/>
						</presentationQuantity>
					</strength>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/PALBOCICLIB100"/>
		<resource>
			<Ingredient>
				<id value="PALBOCICLIB100"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="G9ZF61LE7G"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="ACTIB"/>
						<display value="active ingredient - basis of strength"/>
					</coding>
				</role>
				<group>
					<coding>
						<system value="http://ncimeta.nci.nih.gov"/>
						<code value="N0000175605"/>
						<display value="Kinase Inhibitor"/>
					</coding>
				</group>
				<description value="PALBOCICLIB 100mg"/>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                        <reference>
							<reference value="SubstanceDefinition/palbociclib"/>
						</reference>
                    </code>
					<strength>
						<presentationQuantity>
							<system value="http://unitsofmeasure.org"/>
							<value value="100"/>
							<unit value="mg"/>
							<code value="mg"/>
						</presentationQuantity>
					</strength>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/PALBOCICLIB125"/>
		<resource>
			<Ingredient>
				<id value="PALBOCICLIB125"/>
				<identifier>
					<use value="official"/>
					<system value="http://fdasis.nlm.nih.gov"/>
					<value value="G9ZF61LE7G"/>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="ACTIB"/>
						<display value="active ingredient - basis of strength"/>
					</coding>
				</role>
				<group>
					<coding>
						<system value="http://ncimeta.nci.nih.gov"/>
						<code value="N0000175605"/>
						<display value="Kinase Inhibitor"/>
					</coding>
				</group>
				<description value="PALBOCICLIB 125mg"/>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                        <reference>
							<reference value="SubstanceDefinition/palbociclib"/>
						</reference>
                    </code>
					<strength>
						<presentationQuantity>
							<system value="http://unitsofmeasure.org"/>
							<value value="125"/>
							<unit value="mg"/>
							<code value="mg"/>
						</presentationQuantity>
					</strength>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="SubstanceDefinition/palbociclib"/>
		<resource>
			<SubstanceDefinition>
				<id value="palbociclib"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
					<value value="9QHX048FRV"/>
				</identifier>
				<version value="1"/>
				<status>
					<coding>
						<system value="https://gsrs.ncats.nih.gov/ginas/app/beta/"/>
						<code value="1"/>
						<display value="Validated (UNII)"/>
					</coding>
				</status>
				<name>
					<name value="palbociclib"/>
				</name>
			</SubstanceDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/SILICON-DIOXIDE"/>
		<resource>
			<Ingredient>
				<id value="SILICON-DIOXIDE"/>
				<identifier>
					<coding>
						<system value="http://fdasis.nlm.nih.gov"/>
						<value value="ETJ7Z6XBU4"/>
					</coding>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
                        <concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="ETJ7Z6XBU4"/>
								<display value="SILICON DIOXIDE"/>
							</coding>
						</concept>
                    </code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="Ingredient/TITANIUM-DIOXIDE"/>
		<resource>
			<Ingredient>
				<id value="SUCCINIC-ACID"/>
				<identifier>
					<coding>
						<system value="http://fdasis.nlm.nih.gov"/>
						<value value="AB6MNQ6J6L"/>
					</coding>
				</identifier>
				<status value="active"/>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</for>
				<for>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</for>
				<role>
					<coding>
						<system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass"/>
						<code value="IACT"/>
						<display value="inactive ingredient"/>
					</coding>
				</role>
				<allergenicIndicator value="false"/>
				<substance>
					<code>
					<concept>
							<coding>
								<system value="http://fdasis.nlm.nih.gov"/>
								<code value="AB6MNQ6J6L"/>
								<display value="SUCCINIC ACID"/>
							</coding>
						</concept>
				</code>
				</substance>
			</Ingredient>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
		<resource>
			<ManufacturedItemDefinition>
				<id value="MID-PALBOCICLIB75"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="0069-0187"/>
				</identifier>
				<manufacturedDoseForm>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C25158"/>
						<display value="CAPSULE"/>
					</coding>
				</manufacturedDoseForm>
				<unitOfPresentation>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C48480"/>
						<display value="CAPSULE"/>
					</coding>
				</unitOfPresentation>
				<manufacturer>
					<reference value="Organization/341970073"/>
				</manufacturer>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48556"/>
							<display value="Structured Product Labeling Color"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48327"/>
							<display value="PURPLE"/>
						</coding>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48557"/>
							<display value="Structured Product Labeling Shape"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48348"/>
							<display value="ROUND"/>
						</coding>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLSIZE"/>
						</coding>
					</type>
					<valueQuantity>
						<value value="10"/>
						<unit value="millimeter"/>
						<system value="https://unitsofmeasure.org"/>
						<code value="mm"/>
					</valueQuantity>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLIMPRINT"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<text value="Pfizer;PBC;75"/>
					</valueCodeableConcept>
				</property>
			</ManufacturedItemDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
		<resource>
			<ManufacturedItemDefinition>
				<id value="MID-PALBOCICLIB100"/>
				<identifier>
					<coding>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="0069-0188"/>
					</coding>
				</identifier>
				<manufacturedDoseForm>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C25158"/>
						<display value="CAPSULE"/>
					</coding>
				</manufacturedDoseForm>
				<unitOfPresentation>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C48480"/>
						<display value="CAPSULE"/>
					</coding>
				</unitOfPresentation>
				<manufacturer>
					<reference value="Organization/341970073"/>
				</manufacturer>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48556"/>
							<display value="Structured Product Labeling Color"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48329"/>
							<display value="GREEN"/>
						</coding>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48557"/>
							<display value="Structured Product Labeling Shape"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48345"/>
							<display value="OVAL"/>
						</coding>
						<text value="OVAL"/>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLSIZE"/>
						</coding>
					</type>
					<valueQuantity>
						<value value="15"/>
						<unit value="millimeter"/>
						<system value="https://unitsofmeasure.org"/>
						<code value="mm"/>
					</valueQuantity>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLIMPRINT"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<text value="Pfizer;PBC;100"/>
					</valueCodeableConcept>
				</property>
			</ManufacturedItemDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
		<resource>
			<ManufacturedItemDefinition>
				<id value="MID-PALBOCICLIB125"/>
				<identifier>
					<coding>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="0069-0189"/>
					</coding>
				</identifier>
				<manufacturedDoseForm>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C25158"/>
						<display value="CAPSULE"/>
					</coding>
				</manufacturedDoseForm>
				<unitOfPresentation>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C48480"/>
						<display value="CAPSULE"/>
					</coding>
				</unitOfPresentation>
				<manufacturer>
					<reference value="Organization/341970073"/>
				</manufacturer>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48556"/>
							<display value="Structured Product Labeling Color"/>
						</coding>
						<text value="COLOR"/>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48327"/>
							<display value="PURPLE"/>
						</coding>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48557"/>
							<display value="Structured Product Labeling Shape"/>
						</coding>
						<text value="SHAPE"/>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48345"/>
							<display value="OVAL"/>
						</coding>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLSIZE"/>
						</coding>
					</type>
					<valueQuantity>
						<value value="16"/>
						<unit value="millimeter"/>
						<system value="https://unitsofmeasure.org"/>
						<code value="mm"/>
					</valueQuantity>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLIMPRINT"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<text value="Pfizer;PBC;125"/>
					</valueCodeableConcept>
				</property>
			</ManufacturedItemDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
		<resource>
			<MedicinalProductDefinition>
				<id value="MPDPALBOCICLIB75"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="0069-0187"/>
				</identifier>
				<route>
					<coding>
						<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
						<code value="C38288"/>
						<display value="ORAL"/>
					</coding>
				</route>
				<marketingStatus>
					<status>
						<coding>
							<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses"/>
							<code value="active"/>
						</coding>
					</status>
					<dateRange>
						<start value="2015-02-03"/>
					</dateRange>
				</marketingStatus>
				<type>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C121840"/>
						<display value="Approved for Human Use Product"/>
					</coding>
				</type>
				<domain>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C14225"/>
						<display value="Human"/>
					</coding>
				</domain>
				<version value="1"/>
				<status>
					<coding>
						<system value="http://hl7.org/fhir/publication-status"/>
						<code value="active"/>
						<display value="Active"/>
					</coding>
				</status>
				<statusDate value="2020-03-30"/>
				<name>
					<productName value="IBRANCE® (palbociclib) tablets - 75 mg"/>
					<part>
						<part value="palbociclib"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C71898"/>
							</coding>
							<text value="Proprietary Name"/>
						</type>
					</part>
					<part>
						<part value="palbociclib"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C3273150"/>
							</coding>
							<text value="NONPROPRIETARY"/>
						</type>
					</part>
					<part>
						<part value="75 mg"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="220000000004"/>
							</coding>
							<text value="Strength part"/>
						</type>
					</part>
					<part>
						<part value="CAPSULE"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C25158"/>
								<display value="Pharmaceutical dose form part"/>
							</coding>
						</type>
					</part>
					<countryLanguage>
						<country>
							<coding>
								<system value="urn:iso:std:iso:3166"/>
								<code value="US"/>
								<display value="United States of America"/>
							</coding>
						</country>
						<language>
							<coding>
								<system value="urn:iso:std:iso:639"/>
								<code value="EN"/>
								<display value="English"/>
							</coding>
						</language>
					</countryLanguage>
				</name>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C25391"/>
								<display value="ANALYSIS"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/618054084"/>
					</organization>
					<organization>
						<reference value="Organization/985052076"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
					<organization>
						<reference value="Organization/936889401"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C43360"/>
								<display value="MANUFACTURE"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/985052076"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
					<organization>
						<reference value="Organization/936889401"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C84731"/>
								<display value="PACK"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/618054084"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C84732"/>
								<display value="LABEL"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/134489525"/>
					</organization>
				</operation>
			</MedicinalProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
		<resource>
			<MedicinalProductDefinition>
				<id value="MPDPALBOCICLIB100"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="0069-0188"/>
				</identifier>
				<route>
					<coding>
						<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
						<code value="C38288"/>
						<display value="ORAL"/>
					</coding>
				</route>
				<marketingStatus>
					<status>
						<coding>
							<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses"/>
							<code value="active"/>
						</coding>
					</status>
					<dateRange>
						<start value="2015-02-03"/>
					</dateRange>
				</marketingStatus>
				<type>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C121840"/>
						<display value="Approved for Human Use Product"/>
					</coding>
				</type>
				<domain>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C14225"/>
						<display value="Human"/>
					</coding>
				</domain>
				<version value="1"/>
				<status>
					<coding>
						<system value="http://hl7.org/fhir/publication-status"/>
						<code value="active"/>
						<display value="Active"/>
					</coding>
				</status>
				<statusDate value="2020-03-30"/>
				<name>
					<productName value="IBRANCE® (palbociclib) tablets - 100 mg"/>
					<part>
						<part value="palbociclib"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C71898"/>
							</coding>
							<text value="Proprietary Name"/>
						</type>
					</part>
					<part>
						<part value="palbociclib"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C3273150"/>
							</coding>
							<text value="NONPROPRIETARY"/>
						</type>
					</part>
					<part>
						<part value="100 mg"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="220000000004"/>
							</coding>
							<text value="Strength part"/>
						</type>
					</part>
					<part>
						<part value="CAPSULE"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C25158"/>
								<display value="Pharmaceutical dose form part"/>
							</coding>
						</type>
					</part>
					<countryLanguage>
						<country>
							<coding>
								<system value="urn:iso:std:iso:3166"/>
								<code value="US"/>
								<display value="United States of America"/>
							</coding>
						</country>
						<language>
							<coding>
								<system value="urn:iso:std:iso:639"/>
								<code value="EN"/>
								<display value="English"/>
							</coding>
						</language>
					</countryLanguage>
				</name>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C25391"/>
								<display value="ANALYSIS"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/618054084"/>
					</organization>
					<organization>
						<reference value="Organization/985052076"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
					<organization>
						<reference value="Organization/936889401"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C43360"/>
								<display value="MANUFACTURE"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/985052076"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
					<organization>
						<reference value="Organization/936889401"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C84731"/>
								<display value="PACK"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/618054084"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C84732"/>
								<display value="LABEL"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/134489525"/>
					</organization>
				</operation>
			</MedicinalProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
		<resource>
			<MedicinalProductDefinition>
				<id value="MPDPALBOCICLIB125"/>
				<identifier>
					<coding>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="0069-0189"/>
					</coding>
				</identifier>
				<route>
					<coding>
						<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
						<code value="C38288"/>
						<display value="ORAL"/>
					</coding>
				</route>
				<marketingStatus>
					<status>
						<coding>
							<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses"/>
							<code value="active"/>
						</coding>
					</status>
					<dateRange>
						<start value="2015-02-03"/>
					</dateRange>
				</marketingStatus>
				<type>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C121840"/>
						<display value="Approved for Human Use Product"/>
					</coding>
				</type>
				<domain>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C14225"/>
						<display value="Human"/>
					</coding>
				</domain>
				<version value="1"/>
				<status>
					<coding>
						<system value="http://hl7.org/fhir/publication-status"/>
						<code value="active"/>
						<display value="Active"/>
					</coding>
				</status>
				<statusDate value="2020-03-30"/>
				<name>
					<productName value="IBRANCE® (palbociclib) tablets - 125 mg"/>
					<part>
						<part value="palbociclib"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C71898"/>
							</coding>
							<text value="Proprietary Name"/>
						</type>
					</part>
					<part>
						<part value="palbociclib"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C3273150"/>
							</coding>
							<text value="NONPROPRIETARY"/>
						</type>
					</part>
					<part>
						<part value="125 mg"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="220000000004"/>
							</coding>
							<text value="Strength part"/>
						</type>
					</part>
					<part>
						<part value="CAPSULE"/>
						<type>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C25158"/>
								<display value="Pharmaceutical dose form part"/>
							</coding>
						</type>
					</part>
					<countryLanguage>
						<country>
							<coding>
								<system value="urn:iso:std:iso:3166"/>
								<code value="US"/>
								<display value="United States of America"/>
							</coding>
						</country>
						<language>
							<coding>
								<system value="urn:iso:std:iso:639"/>
								<code value="EN"/>
								<display value="English"/>
							</coding>
						</language>
					</countryLanguage>
				</name>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C25391"/>
								<display value="ANALYSIS"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/618054084"/>
					</organization>
					<organization>
						<reference value="Organization/985052076"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
					<organization>
						<reference value="Organization/936889401"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C43360"/>
								<display value="MANUFACTURE"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/985052076"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
					<organization>
						<reference value="Organization/936889401"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C84731"/>
								<display value="PACK"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/618054084"/>
					</organization>
					<organization>
						<reference value="Organization/341970073"/>
					</organization>
				</operation>
				<operation>
					<type>
						<concept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C84732"/>
								<display value="LABEL"/>
							</coding>
						</concept>
					</type>
					<organization>
						<reference value="Organization/134489525"/>
					</organization>
				</operation>
			</MedicinalProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="AdministrableProductDefinition/APD-PALBOCICLIB75"/>
		<resource>
			<AdministrableProductDefinition xmlns="http://hl7.org/fhir">
				<id value="APD-PALBOCICLIB75"/>
				<identifier>
					<coding>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="0069-0187"/>
					</coding>
				</identifier>
				<subject>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</subject>
				<administrableDoseForm>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C25158"/>
						<display value="CAPSULE"/>
					</coding>
				</administrableDoseForm>
				<unitOfPresentation>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C48480"/>
						<display value="CAPSULE"/>
					</coding>
				</unitOfPresentation>
				<producedFrom>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
				</producedFrom>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48556"/>
							<display value="Structured Product Labeling Color"/>
						</coding>
						<text value="COLOR"/>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48327"/>
							<display value="Purple"/>
						</coding>
						<text value="PURPLE"/>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48557"/>
							<display value="Structured Product Labeling Shape"/>
						</coding>
						<text value="SHAPE"/>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48348"/>
							<display value="Round"/>
						</coding>
						<text value="ROUND"/>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLSIZE"/>
						</coding>
						<text value="SIZE"/>
					</type>
					<valueQuantity>
						<value value="10"/>
						<unit value="millimeter"/>
						<system value="https://unitsofmeasure.org"/>
						<code value="mm"/>
					</valueQuantity>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLIMPRINT"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<text value="Pfizer;PBC;75"/>
					</valueCodeableConcept>
				</property>
				<routeOfAdministration>
					<code>
                        <coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C38288"/>
							<display value="Oral Route of Administration"/>
						</coding>
                        <text value="ORAL"/>
                    </code>
					<targetSpecies>
						<code>
                            <coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C14225"/>
								<display value="Human"/>
							</coding>
                            <text value="HUMAN"/>
                        </code>
					</targetSpecies>
				</routeOfAdministration>
			</AdministrableProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="AdministrableProductDefinition/APD-PALBOCICLIB100"/>
		<resource>
			<AdministrableProductDefinition xmlns="http://hl7.org/fhir">
				<id value="APD-PALBOCICLIB100"/>
				<identifier>
					<coding>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="0069-0188"/>
					</coding>
				</identifier>
				<subject>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</subject>
				<administrableDoseForm>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C42931"/>
						<display value="Film Coated Tablet Dosage Form"/>
					</coding>
					<text value="TABLET, FILM COATED"/>
				</administrableDoseForm>
				<unitOfPresentation>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C48480"/>
						<display value="CAPSULE"/>
					</coding>
				</unitOfPresentation>
				<producedFrom>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
				</producedFrom>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48556"/>
							<display value="Structured Product Labeling Color"/>
						</coding>
						<text value="COLOR"/>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48329"/>
							<display value="Green"/>
						</coding>
						<text value="GREEN"/>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48557"/>
							<display value="Structured Product Labeling Shape"/>
						</coding>
						<text value="SHAPE"/>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48345"/>
							<display value="Oval"/>
						</coding>
						<text value="OVAL"/>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLSIZE"/>
						</coding>
						<text value="SIZE"/>
					</type>
					<valueQuantity>
						<value value="15"/>
						<unit value="millimeter"/>
						<system value="https://unitsofmeasure.org"/>
						<code value="mm"/>
					</valueQuantity>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLIMPRINT"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<text value="Pfizer;PBC;100"/>
					</valueCodeableConcept>
				</property>
				<routeOfAdministration>
					<code>
                        <coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C38288"/>
							<display value="Oral Route of Administration"/>
						</coding>
                        <text value="ORAL"/>
                    </code>
					<targetSpecies>
						<code>
                            <coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C14225"/>
								<display value="Human"/>
							</coding>
                            <text value="HUMAN"/>
                        </code>
					</targetSpecies>
				</routeOfAdministration>
			</AdministrableProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="AdministrableProductDefinition/APD-PALBOCICLIB125"/>
		<resource>
			<AdministrableProductDefinition xmlns="http://hl7.org/fhir">
				<id value="APD-PALBOCICLIB125"/>
				<identifier>
					<coding>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="0069-0189"/>
					</coding>
				</identifier>
				<subject>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</subject>
				<administrableDoseForm>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C42931"/>
						<display value="Film Coated Tablet Dosage Form"/>
					</coding>
					<text value="TABLET, FILM COATED"/>
				</administrableDoseForm>
				<unitOfPresentation>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C48480"/>
						<display value="CAPSULE"/>
					</coding>
				</unitOfPresentation>
				<producedFrom>
					<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125"/>
				</producedFrom>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48556"/>
							<display value="Structured Product Labeling Color"/>
						</coding>
						<text value="COLOR"/>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48327"/>
							<display value="Purple"/>
						</coding>
						<text value="PURPLE"/>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48557"/>
							<display value="Structured Product Labeling Shape"/>
						</coding>
						<text value="SHAPE"/>
					</type>
					<valueCodeableConcept>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C48345"/>
							<display value="Oval"/>
						</coding>
						<text value="OVAL"/>
					</valueCodeableConcept>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLSIZE"/>
						</coding>
						<text value="SIZE"/>
					</type>
					<valueQuantity>
						<value value="16"/>
						<unit value="millimeter"/>
						<system value="https://unitsofmeasure.org"/>
						<code value="mm"/>
					</valueQuantity>
				</property>
				<property>
					<type>
						<coding>
							<system value="urn:oid:2.16.840.1.113883.1.11.19255"/>
							<code value="SPLIMPRINT"/>
						</coding>
					</type>
					<valueCodeableConcept>
						<text value="Pfizer;PBC;125"/>
					</valueCodeableConcept>
				</property>
				<routeOfAdministration>
					<code>
                        <coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C38288"/>
							<display value="Oral Route of Administration"/>
						</coding>
                        <text value="ORAL"/>
                    </code>
					<targetSpecies>
						<code>
                            <coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C14225"/>
								<display value="Human"/>
							</coding>
                            <text value="HUMAN"/>
                        </code>
					</targetSpecies>
				</routeOfAdministration>
			</AdministrableProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="PackagedProductDefinition/0069-0187-21"/>
		<resource>
			<PackagedProductDefinition xmlns="http://hl7.org/fhir">
				<id value="0069-0187-21"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="0069-0187-07"/>
				</identifier>
				<name value="75 mg Capsule Bottle Label - 21 tablets"/>
				<type>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C43233"/>
						<display value="Drug Package"/>
					</coding>
				</type>
				<packageFor>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</packageFor>
				<marketingStatus>
					<status>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C53292"/>
							<display value="Marketing"/>
						</coding>
					</status>
					<dateRange>
						<start value="2015-02-03"/>
					</dateRange>
				</marketingStatus>
				<description value="NDC 0069-0187-21

                Pfizer
                
                Ibrance®
                (palbociclib)
                capsules
                
                75 mg
                
                21 Capsules
                
                Rx only"/>
				<manufacturer>
					<reference value="Organization/985052076"/>
				</manufacturer>
				<manufacturer>
					<reference value="Organization/341970073"/>
				</manufacturer>
				<manufacturer>
					<reference value="Organization/936889401"/>
				</manufacturer>
				<packaging>
					<identifier>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="NDC 0069-0187-21"/>
					</identifier>
					<type>
						<coding>
							<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
							<code value="C43169"/>
							<display value="BOTTLE"/>
						</coding>
					</type>
					<quantity value="1"/>
					<shelfLifeStorage>
						<periodQuantity>
							<value value="48"/>
							<unit value="mo"/>
							<system value="https://unitsofmeasure.org"/>
							<code value="mo"/>
						</periodQuantity>
						<specialPrecautionsForStorage>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C101707"/>
								<display value="Recommended Storage Temperature"/>
							</coding>
							<text value="Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack."/>
						</specialPrecautionsForStorage>
					</shelfLifeStorage>
					<property>
						<type>
							<coding>
								<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-characteristicTypes"/>
								<code value="SPLCMBPRDTP"/>
							</coding>
						</type>
						<valueCodeableConcept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C112160"/>
								<display value="Type 0: Not a Combination Product"/>
							</coding>
						</valueCodeableConcept>
					</property>
					<containedItem>
						<item>
							<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75"/>
						</item>
						<amount>
							<value value="21"/>
							<system value="http://unitsofmeasure.org"/>
							<code value="1"/>
						</amount>
					</containedItem>
				</packaging>
			</PackagedProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="PackagedProductDefinition/0069-0188-21"/>
		<resource>
			<PackagedProductDefinition xmlns="http://hl7.org/fhir">
				<id value="0069-0188-21"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="NDC:0069-0188-03"/>
				</identifier>
				<name value="100 mg Capsule Bottle Label - 21 capsules"/>
				<type>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C43233"/>
						<display value="Drug Package"/>
					</coding>
				</type>
				<packageFor>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</packageFor>
				<marketingStatus>
					<status>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C53292"/>
							<display value="Marketing"/>
						</coding>
					</status>
					<dateRange>
						<start value="2015-02-03"/>
					</dateRange>
				</marketingStatus>
				<description value="NDC 0069-0188-21

                Pfizer
                
                Ibrance®
                (palbociclib)
                capsules
                
                100 mg
                
                21 Capsules"/>
				<manufacturer>
					<reference value="Organization/618054084"/>
				</manufacturer>
				<manufacturer>
					<reference value="Organization/341970073"/>
				</manufacturer>
				<packaging>
					<identifier>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="NDC:0069-0188-21"/>
					</identifier>
					<type>
						<coding>
							<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
							<code value="C43169"/>
							<display value="BOTTLE"/>
						</coding>
					</type>
					<quantity value="1"/>
					<shelfLifeStorage>
						<periodQuantity>
							<value value="48"/>
							<unit value="mo"/>
							<system value="https://unitsofmeasure.org"/>
							<code value="mo"/>
						</periodQuantity>
						<specialPrecautionsForStorage>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C101707"/>
								<display value="Recommended Storage Temperature"/>
							</coding>
							<text value="Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack."/>
						</specialPrecautionsForStorage>
					</shelfLifeStorage>
					<property>
						<type>
							<coding>
								<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-characteristicTypes"/>
								<code value="SPLCMBPRDTP"/>
							</coding>
						</type>
						<valueCodeableConcept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C112160"/>
								<display value="Type 0: Not a Combination Product"/>
							</coding>
						</valueCodeableConcept>
					</property>
					<containedItem>
						<item>
							<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
						</item>
						<amount>
							<value value="21"/>
							<system value="http://unitsofmeasure.org"/>
							<code value="1"/>
						</amount>
					</containedItem>
				</packaging>
			</PackagedProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="PackagedProductDefinition/0069-0189-21"/>
		<resource>
			<PackagedProductDefinition xmlns="http://hl7.org/fhir">
				<id value="0069-0189-21"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="NDC:0069-0188-07"/>
				</identifier>
				<name value="125 mg Capsule Bottle Label - 21 capsules"/>
				<type>
					<coding>
						<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
						<code value="C43169"/>
						<display value="BOTTLE"/>
					</coding>
				</type>
				<packageFor>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</packageFor>
				<marketingStatus>
					<status>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C53292"/>
							<display value="Marketing"/>
						</coding>
					</status>
					<dateRange>
						<start value="2015-02-03"/>
					</dateRange>
				</marketingStatus>
				<description value="7 in 1 DOSE PACK; Type 0: Not a Combination Product"/>
				<description value="NDC 0069-0189-21

                Pfizer
                
                Ibrance®
                (palbociclib)
                capsules
                
                125 mg
                
                21 Capsules
                
                Rx only"/>
				<manufacturer>
					<reference value="Organization/618054084"/>
				</manufacturer>
				<manufacturer>
					<reference value="Organization/341970073"/>
				</manufacturer>
				<packaging>
					<identifier>
						<system value="http://hl7.org/fhir/sid/ndc"/>
						<value value="NDC:0069-0188-07"/>
					</identifier>
					<type>
						<coding>
							<system value="http://ncit.nci.nih.gov"/>
							<code value="C43192"/>
							<display value="Dose Pack"/>
						</coding>
					</type>
					<quantity value="1"/>
					<shelfLifeStorage>
						<periodQuantity>
							<value value="48"/>
							<unit value="mo"/>
							<system value="https://unitsofmeasure.org"/>
							<code value="mo"/>
						</periodQuantity>
						<specialPrecautionsForStorage>
							<coding>
								<system value="http://ncit.nci.nih.gov"/>
								<code value="C101707"/>
								<display value="Recommended Storage Temperature"/>
							</coding>
							<text value="Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original blister pack."/>
						</specialPrecautionsForStorage>
					</shelfLifeStorage>
					<property>
						<type>
							<coding>
								<system value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-characteristicTypes"/>
								<code value="SPLCMBPRDTP"/>
							</coding>
						</type>
						<valueCodeableConcept>
							<coding>
								<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
								<code value="C112160"/>
								<display value="Type 0: Not a Combination Product"/>
							</coding>
						</valueCodeableConcept>
					</property>
					<containedItem>
						<item>
							<reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100"/>
						</item>
						<amount>
							<value value="21"/>
							<system value="http://unitsofmeasure.org"/>
							<code value="1"/>
						</amount>
					</containedItem>
				</packaging>
			</PackagedProductDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="RegulatedAuthorization/RA-PALBOCICLIB75"/>
		<resource>
			<RegulatedAuthorization>
				<id value="RA-PALBOCICLIB75"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="0069-0187-03"/>
				</identifier>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<type>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C156642"/>
						<display value="Marketing Authorization"/>
					</coding>
				</type>
				<description value="Pfizer - NDC 0069-0187-03 - IBRANCE® (palbociclib) tablets - 75 mg - 21 tablets - Monthly Box Contains: 3 individual weekly - packs. Each pack contains 7 IBRANCE tablets - (75 mg per tablet). Rx only"/>
				<region>
					<coding>
						<system value="urn:iso:std:iso:3166"/>
						<code value="US"/>
						<display value="United States of America"/>
					</coding>
				</region>
				<status>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C121840"/>
						<display value="Approved for Human Use Product"/>
					</coding>
				</status>
				<statusDate value="2020-03-30"/>
				<validityPeriod>
					<start value="2020-11-01"/>
					<end value=""/>
				</validityPeriod>
				<holder>
					<reference value="Organization/134489525"/>
				</holder>
			</RegulatedAuthorization>
		</resource>
	</entry>
	<entry>
		<fullUrl value="RegulatedAuthorization/RA-PALBOCICLIB100"/>
		<resource>
			<RegulatedAuthorization>
				<id value="RA-PALBOCICLIB100"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="0069-0188-07"/>
				</identifier>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<type>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C156642"/>
						<display value="Marketing Authorization"/>
					</coding>
				</type>
				<description value="Pfizer - NDC 0069-0188-07 - IBRANCE® (palbociclib) tablets - 100 mg per tablet - This weekly pack contains: 7 tablets - Rx only"/>
				<region>
					<coding>
						<system value="urn:iso:std:iso:3166"/>
						<code value="US"/>
						<display value="United States of America"/>
					</coding>
				</region>
				<status>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C121840"/>
						<display value="Approved for Human Use Product"/>
					</coding>
				</status>
				<statusDate value="2020-03-30"/>
				<validityPeriod>
					<start value="2020-11-01"/>
					<end value=""/>
				</validityPeriod>
				<holder>
					<reference value="Organization/134489525"/>
				</holder>
			</RegulatedAuthorization>
		</resource>
	</entry>
	<entry>
		<fullUrl value="RegulatedAuthorization/RA-PALBOCICLIB125"/>
		<resource>
			<RegulatedAuthorization>
				<id value="RA-PALBOCICLIB125"/>
				<identifier>
					<system value="http://hl7.org/fhir/sid/ndc"/>
					<value value="0069-0189-03"/>
				</identifier>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<type>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C156642"/>
						<display value="Marketing Authorization"/>
					</coding>
				</type>
				<description value="Pfizer - NDC 0069-0189-03 - IBRANCE® (palbociclib) tablets - 125 mg - 21 tablets - Monthly Box Contains: 3 individual weekly - packs. Each pack contains 7 IBRANCE tablets - (125 mg per tablet). Rx only"/>
				<region>
					<coding>
						<system value="urn:iso:std:iso:3166"/>
						<code value="US"/>
						<display value="United States of America"/>
					</coding>
				</region>
				<status>
					<coding>
						<system value="http://ncit.nci.nih.gov"/>
						<code value="C121840"/>
						<display value="Approved for Human Use Product"/>
					</coding>
				</status>
				<statusDate value="2020-03-30"/>
				<validityPeriod>
					<start value="2020-11-01"/>
					<end value=""/>
				</validityPeriod>
				<holder>
					<reference value="Organization/134489525"/>
				</holder>
			</RegulatedAuthorization>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/1a2b3c4d-5e6f-7g8h-9i0j-1k2l3m4n5o6p"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="1a2b3c4d-5e6f-7g8h-9i0j-1k2l3m4n5o6p"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="CYP3AInhibitors001"/>
				</identifier>
				<type value="interaction"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<interaction>
					<interactant>
						<itemCodeableConcept>
							<coding>
								<system value="https://example.com/system"/>
								<code value="CYP3AInhibitor"/>
								<display value="CYP3A Inhibitor"/>
							</coding>
						</itemCodeableConcept>
					</interactant>
				</interaction>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/2b3c4d5e-6f7g-8h9i-0j1k-2l3m4n5o6p7q"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="2b3c4d5e-6f7g-8h9i-0j1k-2l3m4n5o6p7q"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="CYP3AInducers002"/>
				</identifier>
				<type value="interaction"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<interaction>
					<interactant>
						<itemCodeableConcept>
							<coding>
								<system value="https://example.com/system"/>
								<code value="CYP3AInducer"/>
								<display value="CYP3A Inducer"/>
							</coding>
						</itemCodeableConcept>
					</interactant>
				</interaction>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/3c4d5e6f-7g8h-9i0j-1k2l-3m4n5o6p7q8r"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="3c4d5e6f-7g8h-9i0j-1k2l-3m4n5o6p7q8r"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="Midazolam003"/>
				</identifier>
				<type value="interaction"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<interaction>
					<interactant>
						<itemCodeableConcept>
							<coding>
								<system value="https://precision.fda.gov/uniisearch/srs/unii/R60L0SM5BC"/>
								<code value="R60L0SM5BC"/>
								<display value="Midazolam"/>
							</coding>
						</itemCodeableConcept>
					</interactant>
				</interaction>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/4d5e6f7g-8h9i-0j1k-2l3m-4n5o6p7q8r9s"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="4d5e6f7g-8h9i-0j1k-2l3m-4n5o6p7q8r9s"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-indication-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="HRHER2NegativeBreastCancer001"/>
				</identifier>
				<type value="indication"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<indication>
					<code>
                        <coding>
							<system value="http://snomed.info/sct"/>
							<code value="444615000"/>
							<display value="Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"/>
						</coding>
                    </code>
				</indication>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/6f7g8h9i-0j1k-2l3m-4n5o-6p7q8r9s0t1u"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="6f7g8h9i-0j1k-2l3m-4n5o-6p7q8r9s0t1u"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-warning-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="Neutropenia001"/>
				</identifier>
				<type value="warning"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<warning>
					<code>
                        <coding>
							<system value="http://snomed.info/sct"/>
							<code value="703938007"/>
							<display value="Neutropenia"/>
						</coding>
                    </code>
					<description value="Neutropenia was the most frequently reported adverse reaction in PALOMA-2 with an incidence of 80% and PALOMA-3 with an incidence of 83%."/>
				</warning>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/7g8h9i0j-1k2l-3m4n-5o6p-7q8r9s0t1u2v"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="7g8h9i0j-1k2l-3m4n-5o6p-7q8r9s0t1u2v"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-warning-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="ILD002"/>
				</identifier>
				<type value="warning"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<warning>
					<code>
                        <coding>
							<system value="http://snomed.info/sct"/>
							<code value="67782005"/>
							<display value="Interstitial lung disease"/>
						</coding>
                    </code>
					<description value="Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including IBRANCE when taken in combination with endocrine therapy."/>
				</warning>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/8h9i0j1k-2l3m-4n5o-6p7q-8r9s0t1u2v3w"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="8h9i0j1k-2l3m-4n5o-6p7q-8r9s0t1u2v3w"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-warning-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="EmbryoFetalToxicity003"/>
				</identifier>
				<type value="warning"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<warning>
					<code>
                        <coding>
							<system value="http://snomed.info/sct"/>
							<code value="73761001"/>
							<display value="Embryo-Fetal Toxicity"/>
						</coding>
                    </code>
					<description value="Based on findings from animal studies and its mechanism of action, IBRANCE can cause fetal harm when administered to a pregnant woman."/>
				</warning>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/1k2l3m4n-5o6p-7q8r-9s0t-1u2v3w4x5y6z"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="1k2l3m4n-5o6p-7q8r-9s0t-1u2v3w4x5y6z"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="Anemia003"/>
				</identifier>
				<type value="undesirable-effect"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<undesirableEffect>
					<classification>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="271737000"/>
							<display value="Anemia"/>
						</coding>
					</classification>
					<frequency value="≥10%"/>
				</undesirableEffect>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/2l3m4n5o-6p7q-8r9s-0t1u-2v3w4x5y6z7a"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="2l3m4n5o-6p7q-8r9s-0t1u-2v3w4x5y6z7a"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="Thrombocytopenia004"/>
				</identifier>
				<type value="undesirable-effect"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<undesirableEffect>
					<classification>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="302215000"/>
							<display value="Thrombocytopenia"/>
						</coding>
					</classification>
					<frequency value="≥10%"/>
				</undesirableEffect>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/2l3m4n5o-6p7q-8r9s-0t1u-2v3w4x5y6z7a"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="2l3m4n5o-6p7q-8r9s-0t1u-2v3w4x5y6z7a"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="Thrombocytopenia004"/>
				</identifier>
				<type value="undesirable-effect"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<undesirableEffect>
					<classification>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="36225005"/>
							<display value="Blood and lymphatic system disorders"/>
						</coding>
					</classification>
					<symptomConditionEffect>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="302215000"/>
							<display value="Thrombocytopenia"/>
						</coding>
					</symptomConditionEffect>
					<frequency value="≥10%"/>
				</undesirableEffect>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/1k2l3m4n-5o6p-7q8r-9s0t-1u2v3w4x5y6z"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="1k2l3m4n-5o6p-7q8r-9s0t-1u2v3w4x5y6z"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="Anemia003"/>
				</identifier>
				<type value="undesirable-effect"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<undesirableEffect>
					<classification>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="36225005"/>
							<display value="Blood and lymphatic system disorders"/>
						</coding>
					</classification>
					<symptomConditionEffect>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="271737000"/>
							<display value="Anemia"/>
						</coding>
					</symptomConditionEffect>
					<frequency value="≥10%"/>
				</undesirableEffect>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/0j1k2l3m-4n5o-6p7q-8r9s-0t1u2v3w4x5y"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="0j1k2l3m-4n5o-6p7q-8r9s-0t1u2v3w4x5y"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="Leukopenia002"/>
				</identifier>
				<type value="undesirable-effect"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<undesirableEffect>
					<classification>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="36225005"/>
							<display value="Blood and lymphatic system disorders"/>
						</coding>
					</classification>
					<symptomConditionEffect>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="702760002"/>
							<display value="Leukopenia"/>
						</coding>
					</symptomConditionEffect>
					<frequency value="≥10%"/>
				</undesirableEffect>
			</ClinicalUseDefinition>
		</resource>
	</entry>
	<entry>
		<fullUrl value="ClinicalUseDefinition/9i0j1k2l-3m4n-5o6p-7q8r-9s0t1u2v3w4x"/>
		<resource>
			<ClinicalUseDefinition>
				<id value="9i0j1k2l-3m4n-5o6p-7q8r-9s0t1u2v3w4x"/>
				<meta>
					<profile value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi"/>
				</meta>
				<identifier>
					<use value="official"/>
					<system value="https://example.com/system"/>
					<value value="Neutropenia001"/>
				</identifier>
				<type value="undesirable-effect"/>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB75"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB100"/>
				</subject>
				<subject>
					<reference value="MedicinalProductDefinition/MPDPALBOCICLIB125"/>
				</subject>
				<undesirableEffect>
					<classification>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="36225005"/>
							<display value="Blood and lymphatic system disorders"/>
						</coding>
					</classification>
					<symptomConditionEffect>
						<coding>
							<system value="http://snomed.info/sct"/>
							<code value="703938007"/>
							<display value="Neutropenia"/>
						</coding>
					</symptomConditionEffect>
					<frequency value="≥10%"/>
				</undesirableEffect>
			</ClinicalUseDefinition>
		</resource>
	</entry>
			</Bundle>
		</resource>
	</entry>
</Bundle>
